
==== Front
Biomark Res
Biomark Res
Biomarker Research
2050-7771
BioMed Central London

39294728
654
10.1186/s40364-024-00654-1
Review
Deciphering breast cancer dynamics: insights from single-cell and spatial profiling in the multi-omics era
Xiong Xin 1
Wang Xin 2
Liu Cui-Cui 1
Shao Zhi-Ming 1
Yu Ke-Da yukeda@fudan.edu.cn

1
1 grid.11841.3d 0000 0004 0619 8943 Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032 China
2 grid.452404.3 0000 0004 1808 0942 Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032 China
18 9 2024
18 9 2024
2024
12 10728 6 2024
10 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
As one of the most common tumors in women, the pathogenesis and tumor heterogeneity of breast cancer have long been the focal point of research, with the emergence of tumor metastasis and drug resistance posing persistent clinical challenges. The emergence of single-cell sequencing (SCS) technology has introduced novel approaches for gaining comprehensive insights into the biological behavior of malignant tumors. SCS is a high-throughput technology that has rapidly developed in the past decade, providing high-throughput molecular insights at the individual cell level. Furthermore, the advent of multitemporal point sampling and spatial omics also greatly enhances our understanding of cellular dynamics at both temporal and spatial levels. The paper provides a comprehensive overview of the historical development of SCS, and highlights the most recent advancements in utilizing SCS and spatial omics for breast cancer research. The findings from these studies will serve as valuable references for future advancements in basic research, clinical diagnosis, and treatment of breast cancer.

Keywords

Breast cancer
Single-cell sequencing
Spatial omics
Tumor heterogeneity
issue-copyright-statement© Yumed Inc. and BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Breast cancer is one of the most common malignant tumors in women, and a study by the World Health Organization's International Agency for Research on Cancer shows that there will be 2.3 million new cases of breast cancer worldwide in 2022 and an estimated 666,000 deaths [1]. Breast cancer is a highly heterogeneous disease, based on the presence of hormone receptor (HR) [estrogen receptor (ER) and progesterone receptor (PR) status], human epidermal growth factor receptor 2 (HER2) status, and the proliferation index Ki67, breast cancer can be classified into four different molecular subtypes [2]: Luminal A, Luminal B, HER2 + , and triple-negative breast cancer (TNBC); according to the intrinsic gene expression characteristics, breast cancer can be classified into five molecular subtypes: Luminal A, Luminal B, Normal-like, HER2-enriched, and Basal-like [3]. For treatment purposes, breast cancer is generally divided into three clinical subtypes: HR-positive/HER2-negative (HR + /HER2-), HER2-positive (HER2 +), and TNBC [HR-negative (HR-), HER2-] [4, 5]. All types of tumors, including breast cancer, are intricate and dynamic diseases, progressing from non-malignant to malignant states, from situ lesions to invasive forms, and from sensitivity to resistance to treatment [6]. Researchers have dedicated considerable efforts over the years to address these complexities, aiming to enhance our understanding of tumors and facilitate the development of more precise treatments.

The emergence of traditional high-throughput sequencing technology has promoted the exploration of the mechanism of tumorigenesis and progression and accelerated the development of precision oncology [7, 8]. However, the results of traditional sequencing technologies present the average signal of many mixed cells and cannot specifically analyze the characteristics of a specific cell population, so there are still some limitations [9, 10]. Unlike traditional sequencing technologies, SCS reveals cellular and microenvironmental features at single-cell resolution and has unique advantages in studying tumorigenesis, metastasis, recurrence, and treatment resistance [11]. The spatial localization characteristics of cells within the tumor microenvironment are also crucial for tumor progression. Using spatial sequencing techniques allows for the matching of sequencing data with the spatial positions of cells, thereby diversifying the perspectives of research [12, 13]. The present article provides a comprehensive overview of the current utilization of SCS and spatial omics in breast cancer research, offering valuable references for comprehending the origin, heterogeneity, metastasis, and drug resistance mechanisms associated with this disease (Fig. 1).Fig. 1 Overview of the application of single-cell and spatial omics in breast cancer. The application of single-cell and spatial omics enables the elucidation of the origin, heterogeneity, and underlying mechanisms governing metastasis and drug resistance in breast cancer. Abbreviations: CAF, Cancer-associated fibroblast

Evolution and basic framework of single-cell sequencing and spatial omics

Single-cell sequencing

Since the publication of the first single-cell RNA sequencing (scRNA-seq) data in 2009 [14], SCS has developed rapidly over the years. In 2013, SCS was recognized as the Method of the Year by Nature Methods [15]. In 2019, single-cell multi-omics technology received the prestigious title of Method of the Year from Nature Methods [16]. Presently, SCS has found applications in various medical fields such as oncology [11], pharmacy [17], infectious diseases [18], botany [19, 20], and entomology [21, 22]. SCS mainly includes single-cell genomics [23], single-cell transcriptomics [24], single-cell proteomics [25], single-cell epigenomics [26], single-cell metabolomics [27], and single-cell multi-omics [28], etc. There are multiple well-established commercial sequencing platforms accessible to researchers, such as 10X Genomics [29] and BD Rhapsody [30].

The scRNA-seq is the most widely used SCS technology. Taking scRNA-seq as an example, the main steps of scRNA-seq encompass tissue dissociation, isolation and capture of individual cells, nucleic acid amplification, library construction, high-throughput sequencing, and data analysis [31, 32]. The isolation and capture of individual cells ensure the acquisition of gene expression information for each cell in subsequent steps, distinguishing scRNA-seq from traditional bulk RNA sequencing (Fig. 2).Fig. 2 Differences between bulk RNA sequencing and scRNA-seq. Taking RNA sequencing as an example, we can illustrate the distinction between traditional bulk sequencing and SCS (10 × Genomics). Bulk RNA sequencing (Bulk RNA-seq) provides average information obtained from a mixture of cells, commonly utilized for analyzing intergroup differences in gene expression. scRNA-seq dissects tissues into individual cells to capture gene expression profiles at a single-cell level, enabling comparisons of group-specific variations

Data analysis in scRNA-seq is a complex and time-consuming process that has led to the development of various computational tools for analyzing and visualizing scRNA-seq data [33]. Seurat [34] and scanpy [35] are the primary toolkits used for preliminary processing of scRNA-seq data such as quality control, dimensional reduction clustering, and cell type identification. Additionally, multiple adjunct data analysis processes enable further exploration of single-cell data for more efficient utilization. For instance, Monocle3 is a quasi-temporal analysis toolkit that utilizes scRNA-seq data to infer cell developmental trajectories allowing the discovery of cellular lineage relationships and differentiation status [36]. Cellchat facilitates cell communication analysis by quantitatively describing intercellular communication networks while predicting ligand-receptor interactions between different cells [37]. SCENIC focuses on transcription factors within scRNA-seq datasets to establish gene regulatory networks, providing insights into critical regulators across distinct cell types [38].

Other single-cell sequencing technologies

The progression from genome to transcriptome, proteome, and ultimately phenotype is a complex, diverse, and non-linear phenomenon [39, 40]. In addition to integrating multiple SCS technologies for comprehensive information acquisition, single-cell multi-omics technologies enable simultaneous retrieval of various types of data in a single sequencing experiment [28]. For instance, the DR-seq (gDNA-mRNA sequencing) enables the simultaneous acquisition of genomic and transcriptomic information [41], and SNARE-seq (single-nucleus chromatin accessibility and mRNA expression sequencing) allows for concurrent profiling of epigenetic and transcriptomic features [42]. The emergence and application of these technologies enable us to extract a greater amount of information from a sample, thereby significantly saving time and enhancing the diversity of obtained information.

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated nuclease 9 (CRISPR/Cas9) genome editing system has been a powerful genome engineering tool, which allows scientists to precisely alter DNA sequences, enabling the observation of cell phenotypes mediated by specific genes [43, 44]. Notably, the single-cell CRISPR screening technology (produced by combining SCS and CRISPR/Cas9 genome editing system) has significantly enhanced the efficacy of gene editing [45]. This advanced technique enables the simultaneous capture of CRISPR single guide RNA and transcriptome information from individual cells, facilitating multi-gene screening within a single experiment and unveiling the potential functional implications of targeted genes [46–48].

Spatial omics

Although SCS can provide a wealth of information at an exceptionally high resolution, it offers a partial view. For instance, while scRNA-seq enables the identification of distinct cell types, it lacks spatial information about their locations. The emergence of spatial sequencing technologies solves this limitation well.

In 2020, spatially resolved transcriptomics was recognized as the Method of the Year by Nature Methods [49]. The rapid development of spatial omics can be attributed to the advancements in imaging, omics analysis, sequencing, mass spectrometry, image analysis, and bioinformatics [50]. Spatial sequencing technologies use special processing methods to obtain cellular transcriptomic, proteomic, and metabolomic information while preserving the original spatial location of cells in tumor tissue slices [12, 13, 51]. Different spatial sequencing technologies employ distinct methods for acquiring spatial location information. For instance, stereo-seq, a technique for spatial transcriptome sequencing, utilizes in-situ sequencing of spatial barcodes (capture probes—DNA oligonucleotides) to obtain spatial coordinates [52]. On the other hand, CODEX, a technology for spatial protein sequencing, enables the determination of protein locations through multiplexed antibody detection [53]. The processing and analysis of spatial sequencing data are inherently complex, necessitating advanced bioinformatics expertise from researchers [51, 54].

The integration of spatial sequencing data with SCS data is frequently employed in practical applications. By integrating scRNA-seq and spatial transcriptomics data to achieve complementary strengths, gene expression signatures, spatial location localization of cells, and their proximity to each other can be obtained, further deepening our understanding of diseases [55]. Currently, spatial transcriptomics sequencing has been widely used in the study of a variety of tumors, including breast cancer [56], hepatocellular carcinoma [57], colorectal cancer [58], and kidney cancer [59]. Moreover, the combination of high-resolution imaging techniques with mass spectrometry enables spatial proteomics to provide precise information on the distribution and localization of proteins in cells or tissues [60, 61]. The application of spatial proteomics enables the analysis of tumor heterogeneity at the protein level, facilitating the identification of pivotal factors driving tumor progression [62–65]. Metabolic abnormality is a hallmark of tumors, with the most well-known being the Warburg effect [66]. Tumor metabolic characteristics exhibit heterogeneity [67]. Spatial metabolomics is increasingly advancing and enables the assessment of cellular metabolism status in different regions of tumor tissue slices [68, 69], facilitating comprehensive analysis of region-specific metabolic profiles and further exploration into tumor metabolism heterogeneity [70–72].

Overall, with the advancement of sequencing technology, an increasing number of SCS and spatial sequencing technologies and commercial platforms are gradually being introduced, enabling researchers to select one or multiple sequencing technologies/commercial platforms based on their research objectives [14, 41, 42, 52, 53, 73–142] (Fig. 3). In addition, the establishment of public databases has significantly enhanced the popularity of SCS technology and spatial omics, enabling multiple databases to be utilized for data acquisition or analysis in the field of SCS and spatial omics [143–164] (Table 1).Fig. 3 Summary of some important SCS and spatial sequencing technologies and commercial sequencing platforms. Since the pioneering work by Tang et al. in 2009, SCS has witnessed rapid advancements encompassing genomics, transcriptomics, proteomics, epigenomics, metabolomics, spatial omics, and multi-omics. Furthermore, a plethora of well-established commercial platforms have emerged to cater to the diverse needs of researchers. The scatterplot depicted in this diagram illustrates the chronological order of their release dates. The release timing of the commercial platform is contingent upon its public listing schedule

Table 1 Public databases for single-cell and spatial omics in the medical field

Database	Availability	Function	References	
GEO	https://www.ncbi.nlm.nih.gov/geo/	Data download	[143]	
The Human Cell Atlas	https://data.humancellatlas.org/	Data download	[144]	
CellMarker 2.0	http://bio-bigdata.hrbmu.edu.cn/CellMarker/	Data analysis	[145]	
ColorCells	https://rna.sysu.edu.cn/colorcells/index.php	Data analysis	[146]	
Human Cell Landscape	https://bis.zju.edu.cn/HCL/	Data analysis	[147]	
Mouse Cell Atlas	https://bis.zju.edu.cn/MCA/index.html	Data analysis	[148]	
scTPA	http://sctpa.bio-data.cn/sctpa/	Data analysis	[149]	
TISCH	http://tisch.comp-genomics.org/home/	Data analysis	[150]	
SPDB	https://scproteomicsdb.com/	Data analysis	[151]	
SODB	https://gene.ai.tencent.com/SpatialOmics/	Data analysis	[152]	
BloodSpot	https://www.fobinf.com/	Data analysis	[153]	
SPASCER	https://ccsm.uth.edu/SPASCER/	Data download/Data analysis	[154]	
SCPortalen	https://single-cell.riken.jp/SCPortalen_Database/	Data download/Data analysis	[155]	
SpatialDB	https://www.spatialomics.org/SpatialDB	Data download/Data analysis	[156]	
STOmicsDB	https://db.cngb.org/stomics/	Data download/Data analysis	[157]	
Tabula Muris	https://tabula-muris.ds.czbiohub.org/	Data download/Data analysis	[158]	
PanglaoDB	https://panglaodb.se/	Data download/Data analysis	[159]	
Jinglebells	https://jinglebells.bgu.ac.il/	Data download/Data analysis	[160]	
Cell BLAST	https://cblast.gao-lab.org/	Data download/Data analysis	[161]	
DISCO	https://www.immunesinglecell.org/	Data download/Data analysis	[162]	
CancerSEA	http://biocc.hrbmu.edu.cn/CancerSEA/	Data download/Data analysis	[163]	
SC2disease	http://easybioai.com/sc2disease/	Data download/Data analysis	[164]	

Single-cell sequencing and spatial omics reveal the origin of breast cancer

Breast cancer originates in breast epithelial cells, and the origin cells of different breast cancer subtypes may be different [165]. Lim E et al. [166] classified normal breast epithelial cells from BRCA1 mutation carriers into three types: basal, mature luminal, and luminal progenitor cells based on flow cytometry, and the Basal-like subtype of breast cancer showed high expression of the luminal progenitor cells gene signature, while the Luminal A and Luminal B subtypes exhibited high expression of the mature luminal cells gene signature, suggesting variability in the origins of different molecular subtypes of breast cancer.

Nguyen QH et al. [167] used scRNA-seq to obtain the transcriptome data of 25,790 primary human mammary epithelial cells from 7 individuals and found that normal mammary epithelial cells could be divided into three cell types: basal (KRT14+), luminal-1 (KRT18+SLPI+), luminal-2 (KRT18+ANKRD30A+). The gene scoring method revealed that the gene expression characteristics of the three normal breast epithelial cells of different breast cancer subtypes were different, demonstrating the possibility that different breast cancer subtypes had different origins. Other researchers have also identified 23 distinct subpopulations of normal breast epithelial cells, of which three mature luminal-like subpopulations and one luminal progenitor-like subpopulation may be the cell population that tend to develop into tumors [168]. Gray GK et al. [169] integrated single-cell transcriptome and proteome sequencing data to classify luminal progenitor cells into two distinct subtypes: basal-luminal (BL) and AV progenitor (AP). It was observed that the BL subtype exhibits an age-related accumulation pattern, with genomic characteristics resembling those of Basal-like breast cancer. Based on single-cell chromatin analysis, normal breast cells can also be classified into three subtypes: basal/myoepithelial (BM), luminal progenitor (LP), and mature luminal (ML) [170]. By comparing the scRNA-seq data of normal breast tissue and breast cancer, researchers found that the gene expression patterns of the Basal-like and Normal-like subtypes of breast cancer are more similar to the BM and LP subtypes of normal breast epithelium, while the Luminal A and Luminal B subtypes exhibit gene expression patterns similar to the ML subtype of normal breast epithelium [171].

Age is considered one of the significant risk factors for breast cancer [172]. To investigate the impact of aging on breast cancer, Li CM et al. [173] conducted scRNA-seq analysis on normal mammary tissues obtained from young and old mice. Their findings revealed a higher abundance of luminal progenitor cells in the mammary tissues of old mice, alterations in basal epithelial function, and an overall pro-inflammatory microenvironment within the tissue. These results provided insights into the underlying mechanisms linking aging to increased susceptibility to breast cancer. Pelissier Vatter FA et al. [174] conducted a single-cell proteome analysis of normal mammary epithelial cells from a cohort of 57 women aged 16 to 91. Their findings revealed that a specific subset of the apical luminal epithelium exhibited characteristics similar to Basal-like breast cancer, displaying enhanced cell adhesion and migration capabilities, progressively accumulating with age, thereby indicating an increased susceptibility to breast cancer.

Women with mutations in the BRCA1 gene have an increased risk of developing breast cancer and a tendency to establish Basal-like breast cancer [175]. However, the underlying mechanisms remain unclear. By comparative analysis of scRNA-seq data from breast cancer tissues of BRCA1 mutation carriers and non-carriers, as well as from normal breast tissues, the investigators found that Basal-like breast cancer and Luminal breast cancer may originate from Luminal progenitor cells and mature Luminal cells, respectively [176]. In addition to focusing on epithelial cells, the researchers discovered that pre-cancer-associated fibroblasts of individuals with BRCA1 mutations produce tumorigenic factors that induce the accumulation of luminal progenitor cells and promote the develogtpment of breast cancer [177]. A recent study utilizing scRNA-seq data including over 800,000 normal breast tissue cells revealed that the immune cells of individuals with BRCA1/BRCA2 mutations exhibit the expression of genes associated with immune exhaustion, suggesting the likelihood of immune evasion preceding tumor onset [178].

Exploring breast cancer heterogeneity with single-cell sequencing and spatial omics

Heterogeneity is one of the hallmarks of tumors, which often affects the oncogenesis, tumor progression, and treatment [179]. The causes of tumor heterogeneity remain unclear, and mainstream viewpoints include the tumor stem cell model [180] and the clonal evolution model [181]. In breast cancer, tumor heterogeneity is also very obvious [182]. The classical typing of breast cancer includes immunohistochemistry typing [2] and PAM50 typing [3]. With the deepening of research, multiple subtypes of a particular type of breast cancer have been classified, such as Lehmann BD et al. [183], who classified TNBC into six subtypes, Jiang YZ et al. [184], who classified TNBC into four subtypes, and Jin X et al. [185], who classified HR + /HER2- breast cancer into four subtypes. Different molecular subtypes of breast cancer have different therapeutic responses and clinical prognoses. Understanding the heterogeneity of breast cancer is of great significance for tumor prevention, clinical diagnosis and treatment [186]. SCS can describe the tumor landscape from the perspective of single cells, providing a new perspective for understanding the heterogeneity of tumor [187].

Epithelial cells heterogeneity

Identifying the characteristics of normal breast tissue epithelial cells helps to understand the heterogeneity of breast cancer. As previously mentioned, SCS reveals that normal breast epithelial cells are composed of multiple cell types and exhibit considerable heterogeneity, which may explain the origin of different subtypes of breast cancer [167, 168].

In 2011, Navin N et al. [73] used SCS to study 100 tumor cells from two breast cancer patients and found that the tumor epithelium could be divided into three different clonal subgroups, and one single clonal subgroup will proliferate to form the primary tumor and spread to form metastasis. In 2018, Karaayvaz M et al. [188] analyzed scRNA-seq data of more than 1,500 cells from 6 TNBC breast cancer patients and found that tumor cells in different patients were composed of multiple different subgroups, and there were shared subgroups and self-specific subgroups among different patients. Moreover, the gene expression characteristics of a shared subgroup can also predict the prognosis of patients. In 2021, Wu SZ et al. [56] developed an intrinsic typing method (scSubtype) based on the scRNA-seq results of 26 patients with primary breast cancer (11 ER + , 5 HER2 + , and 10 TNBC). The scSubtype analysis revealed that in a single tumor sample, tumor cells consisted of multiple scSubtype molecular types that did not precisely match the histological type, reflecting the intratumoral heterogeneity of breast cancer. To investigate the impact of intratumoral heterogeneity on tumor prognosis, Xu L et al. [189] integrated 8 publicly available breast cancer scRNA-seq datasets to construct a comprehensive single-cell atlas comprising over 230,000 cells. They categorized tumor cells into ten distinct subpopulations through unsupervised and supervised clustering methods. They also developed a computational model called InteractPrint to assess the interactions between tumor cells and immune cells quantitatively. Notably, their findings demonstrated that the InteractPrint analysis of T cells could predict the therapeutic response of tumors to immune checkpoint blockade (ICB). The heterogeneity of breast cancer tumor cells are also reflected in spatial localization. When SCS was combined with spatial transcriptome sequencing, it was discovered that distinct subpopulations of tumor cells exhibited varying distribution patterns within the tumor [190].

Microenvironment cells heterogeneity

Tumor is a complex disease. Besides the tumor cells themselves, the cellular and non-cellular components of the tumor microenvironment play a vital role in the process of tumorigenesis, metastasis, and recurrence [13]. The tumor microenvironment exhibits heterogeneity in composition and functional state, which arises from variations in tumor sites, intrinsic characteristics of tumor cells, tumor stages, and inter-individual differences among patients [191]. The cellular components of the tumor microenvironment mainly include immune cells such as T cells, B cells, monocytes, macrophages, and stromal cells such as fibroblasts, and the plasticity and heterogeneity of these cells influence tumor progression [192–196]. The application of SCS provides a more microscopic perspective for us to further analyze the cell heterogeneity in the microenvironment of different solid tumors [197, 198].

Immune cells

Savas P et al. [199] conducted SCS on 6311 T cells isolated from human breast cancer samples and identified 10 T cell clusters, revealing the significant heterogeneity of T cells. The authors focused on a subgroup of CD8+CD103+ T cells with tissue-resident memory T cell properties, which expressed multiple cytotoxic effector molecules and immune checkpoint molecules at high levels, and the gene expression characteristics of this cell subgroup were positively correlated with good prognosis in early TNBC patients. Azizi E et al. [200] constructed a scRNA-seq map of 47,016 CD45+ cells from tumor tissue samples, tumor metastatic lymph nodes, paired normal tissues, and peripheral blood from 8 breast cancer patients. By integrating all sequencing data, it was found that all immune cells could be divided into 38 T cell clusters, 27 myeloid cell clusters, 9 B cell clusters, and 9 NK cell clusters. Although tumor tissue, lymph nodes, normal breast tissue, and peripheral blood share some cell clusters, both cell types and cell abundance are further increased in tumors, demonstrating the complexity of the tumor microenvironment. Pal B et al. [201] used scRNA-seq to carefully compare the immune microenvironment characteristics of different breast cancer subtypes, revealing the cell diversity among different breast cancer subtypes. Wagner J et al. [202] drew a single-cell proteomic atlas of 144 tumor samples (including four breast cancer subtypes), 46 para-cancerous tissue samples, and 4 non-cancerous breast tissue samples. They made a detailed classification of epithelial cells, T cells, and myeloid cells. Different epithelial clusters, T cell clusters, and myeloid cell clusters are distributed differently in tumor tissue, paracancer tissue, and normal breast tissue, as well as among different breast cancer molecular subtypes, confirming the internal heterogeneity of different breast cancer molecular subtypes and suggesting the reasons for different responses to ICB. Programmed death ligand 1 (PD-L1) is predominantly expressed by tumor cells and is generally believed to exert immunosuppressive effects, leading to immune evasion by tumors [203]. Recent studies have indicated that tumor-associated macrophages (TAMs) can also exhibit high levels of PD-L1 expression [204]; however, the biological significance of these TAMs remains unclear. Utilizing scRNA-seq and spatial immunofluorescence staining techniques, Wang et al. [205] discovered that PD-L1+ TAMs possess immune-activating properties and are spatially adjacent to T cells. In vitro experiments further demonstrated that these TAMs can enhance the proliferation and cytotoxicity of CD8+ T cells. Moreover, in two independent breast cancer datasets, the presence of PD-L1+ TAMs was associated with a favorable prognosis.

Stromal cells

Cancer-associated fibroblasts (CAFs) are considered an important factor in promoting tumor progression and are highly heterogeneous cells [196]. In mouse models, SCS identified three types of CAFs: vascular CAFs (vCAFs), stromal CAFs (mCAFs), and developmental CAFs (dCAFs), all of which differ in their gene expression characteristics, origin, and spatial location. The above three types of CAFs also exist in human tumors, and the gene expression characteristics of vCAF and mCAF are independent predictors of metastasis of human breast cancer [206]. According to a previous study, CAFs in human breast cancer can be divided into four types: CAF-S1, CAF-S2, CAF-S3, and CAF-S4, and CAF-S1 is related to immunosuppressive microenvironment [207]. Cords et al. [208] conducted scRNA-seq on stromal cells of 14 breast cancer patients. Based on the sequencing results, nine types of CAFs and a type of pericytes were defined. Different subgroups of CAFs had different high-expression genes and functional states, which may guide clinical treatment in the future. To further investigate the role of various types of CAFs in tumor progression, Ye J et al. [209] identified a novel subgroup of CAFs called senescent CAFs (senCAFs) using publicly available scRNA-seq data. It was observed that senCAFs could suppress the toxicity of NK cells, thereby promoting tumor growth. Targeting senCAFs could potentially alleviate NK cell inhibition and restrict tumor growth. Kieffer Y et al. [210] individually sorted CAF-S1 from eight breast cancer samples by flow cytometry, identified eight distinct CAF-S1 subpopulations (ecm-myCAF/detox-iCAF/IL-iCAF/TGFβ-myCAF/wound-myCAF/IFNγ-iCAF/IFNαβ-myCAF/acto-myCAF) by using scRNA-seq. Croizer H et al. further investigated the function, plasticity, and spatial distribution of these subpopulations [211]. The results revealed that ecm-myCAF is associated with various immunosuppressive cells, such as TREM2+ macrophages, regulatory NK cells, and regulatory T cells. On the other hand, detox-iCAF is associated with immunoprotective FOLR2+ macrophages. In vitro and in vivo experiments demonstrated that tumor cells can induce the transformation of detox-iCAF into ecm-myCAF.

Growth disorders and abnormal functioning of blood vessels are indicative signs of tumors. Endothelial cells (ECs), the primary constituents of blood vessels, play a crucial role in regulating tumorigenesis and progression [212, 213]. ECs can be broadly categorized into ECs and vascular ECs, with the latter encompassing arterial, venous, and capillary ECs [214]. The advent of SCS has facilitated the analysis of EC’s plasticity and interactions with other cell types [215]. Geldhof V et al. [216] analyzed scRNA-seq data of 8433 breast cancer-associated ECs, revealing previously unreported potential interactions between these cells and immune cells that suggest possible immunomodulatory functions of ECs. Additionally, they identified a capillary EC subtype (Lipid processing endothelial cell: LIPEC) with high levels of expression of lipid metabolism genes. The retrospective analysis revealed that LIPEC was associated with a significantly improved prognosis in breast cancer patients treated with metformin.

Application of single-cell sequencing in the study of breast cancer metastasis mechanism

Metastasis occurs in approximately 20–30% of breast cancer patients, and the 5-year overall survival rate of patients without distant metastasis can reach 80%, while the occurrence of distant metastasis can reduce this rate to 25% [217]. Almost all deaths of breast cancer patients are attributed to tumor metastasis [218], so the exploration of the mechanism of breast cancer metastasis is of great clinical value. The mechanism of breast cancer metastasis has been widely reported, involving many aspects [219–223]. SCS can provide new perspectives and ideas for studying metastatic mechanisms, which is conducive to revealing the differences in genetic, transcriptional, and metabolic features between primary and metastatic tumors.

An essential step in tumor metastasis is to break through the basement membrane and develop into invasive tumors [224]. To explore how breast ductal carcinoma in situ progresses into invasive ductal carcinoma, Casasent AK et al. [225] combined exon sequencing with topographic single cell sequencing to conduct an in-depth analysis of 1293 tumor cells from 10 breast cancer patients and trace the clonal evolution of their invasion process. Based on the sequencing data, the researchers reached three important conclusions: first, the genome of tumor cells evolved before the tumor cells broke through the basement membrane; second, the tumor subclones in breast ducts were all derived from single cells; third, tumor cell population that break through the basement membrane and migrate to neighboring tissues were derived from one or more clones.

The final step of tumor metastasis is colonization at distant sites, and the microenvironment at the sites of metastasis affects the ability of the tumors to metastasize to these sites [226]. Zou Y et al. [227] used scRNA-seq for the first time to analyze the microenvironment characteristics of brain and liver metastases in breast cancer. At the sites of metastasis, a variety of immunosuppressive cells such as FOXP3+ regulatory T (Treg) cells, LAMP3+ tolerogenic dendritic cells, CCL18+ M2-like macrophages, RGS5+ CAFs and LGALS1+ microglia cells increased significantly. The study also identified KLF5 as a potent target for inhibiting breast cancer metastasis, with inhibitors that effectively inhibit the migration ability of breast cancer cell lines. The lymph node is the primary site of metastasis for a variety of solid tumors, including breast cancer [228] and tumors can metastasize to distant sites through lymph nodes [229], so understanding the mechanism of lymph node metastasis can provide a reference for clinical blocking of tumor lymph node metastasis. Lei PJ et al. [230] used a 4T1 mouse breast cancer model to study how tumor cells could metastasize and survive in lymph nodes. By conducting scRNA-seq analysis on paired samples of tumor primary and lymph node metastases, they discovered that the expression of genes controlling the expression of major histocompatibility complex (MHC) class II molecules were increased in tumor cells in lymph nodes, and the expression of costimulatory molecules was lacking, resulting in the decrease of CD4+ effector T cells and the increase of immunosuppressive Treg cells in lymph nodes. Experimental knockout of MHC-II gene expression in tumor cells resulted in decreased lymph node metastasis and decreased expansion of Treg cells in lymph nodes. Liu T et al. [231] studied the differences in tumor cells and tumor microenvironment between the primary tumor and lymph node metastases in human breast cancer and found that the activation, toxicity, and differentiation of T cells in tumor lymph node metastases were inhibited, while the antigen-presenting pathway of tumor cells was down-regulated. These findings explain why tumor cells can metastasize to lymph nodes. The most common site of distal metastasis of breast cancer is bone [232] and the mechanism of the high propensity of breast cancer to bone metastasis remains elusive. Wu Q et al. [233] first found that SCUBE2 was highly expressed in luminal breast cancer and was related to bone metastasis and verified through experiments that this gene could promote bone metastasis of official breast cancer. To understand the causes of bone metastasis, the researchers conducted scRNA-seq on the bone metastasis niche of SCUBE2-positive tumor cells and bone metastasis niche of SCUBE2-negative tumor cells, and the results showed that osteoblasts were abundant in the former. Further studies have shown that SCUBE2 can mediate the bone metastasis of tubular breast cancer by regulating the immunosuppressive osteoblast niche.

Tumor metabolism is also related to tumor metastasis, and metabolic plasticity is often enhanced during metastasis [234, 235]. How energy metabolism changes during breast cancer metastasis is not fully understood. Davis RT et al. [236] established a mouse transplanted tumor model of human xenogenic breast cancer and combined it with scRNA-seq to study the transcriptome differences between the primary tumor and metastatic tumor and found that the primary tumor and metastatic tumor showed high transcriptional heterogeneity. Pathway enrichment analysis showed that the oxidative phosphorylation pathway was significantly up-regulated in the metastatic tumor. In vitro experiments have also verified that inhibition of the oxidative phosphorylation pathway can lead to reduced metastasis, fully demonstrating the importance of the oxidative phosphorylation pathway in the process of metastasis. In addition, Liu YM et al. [237] used scRNA-seq and spatial transcriptome sequencing to analyze the paired samples of tumor primary sites and lymph node metastases from 4 breast cancer patients and also found that the energy metabolism transition from glycolysis to oxidative phosphorylation occurred in the early disseminated metastatic tumor cell population.

Characteristics of drug resistance in breast cancer revealed by single-cell sequencing and spatial omics

Each subtype of breast cancer has unique biological characteristics and responds differently to drug treatments, necessitating individualized therapeutic approaches [172]. HR + HER2- breast cancer typically requires endocrine therapy, often combined with chemotherapy and targeted therapy; HER2 + breast cancer primarily relies on targeted therapies such as trastuzumab; and TNBC is mainly treated with chemotherapy and immunotherapy [4, 238]. However, the emergence of drug resistance has always posed a clinical challenge for these subtypes of breast cancer, although their resistance mechanisms are not entirely consistent.

HR + /HER2- breast cancer

HR + /HER2- breast cancer accounts for about 70% of all breast cancer cases. Endocrine therapy is one of the standard drug therapies for this breast cancer subtype [239, 240]. For some patients, CDK4/6 inhibitors, PARP inhibitors, and PI3K pathway inhibitors can be added according to the molecular characteristics of the tumors in order to enhance therapeutic efficacy [4, 172, 241]. Although endocrine therapy has achieved a significant effect, some patients still have endocrine therapy resistance, resulting in tumor metastasis or recurrence [242].

Brady SW et al. [243] followed up 4 patients with metastatic ER + breast cancer for many years and used whole genome sequencing, whole exome sequencing and single-cell DNA sequencing (scDNA-seq) to dynamically evaluate the subclonal evolution of patients' tumors during drug therapy. They found that drug-resistant tumor cells were present prior to chemotherapy, and chemotherapy led to the dominance of these cells, resulting in the development of chemotherapy resistance in the tumor. The mesenchymal and growth factor signaling pathways in these cells were upregulated, whereas the antigen presentation and TNF-α signaling pathways were downregulated. Griffiths JI et al. [244] collected tumor tissue samples from 60 postmenopausal women participating who received endocrine therapy and/or CDK4/6 inhibitors treatment at three-time points (at the beginning of treatment, day 14 of treatment, and at the end of treatment), and performed scRNA-seq and whole exon sequencing on these samples. The researchers found that the upregulation of ERBB4 signaling triggered the activation of the RTK signaling pathway to sustain estrogen signaling in drug-resistant tumor cells during endocrine monotherapy; during the combination therapy, the surviving resistant tumor cells exhibited accelerated loss of estrogen signaling and increased activation of growth factor receptor and JNK-MAPK signaling pathways, which facilitated the proliferation of these tumor cells. These results suggest that tumors can reduce their dependence on ER or CDK4/6 activation during endocrine therapy or combination therapy through a series of compensatory mechanisms, thereby circumventing inhibition by endocrine therapy and CDK4/6 inhibitors.

HER2 + breast cancer

HER2 + breast cancer accounts for approximately 20% of all breast cancers and is typically characterized by overexpression of HER2, which is significantly associated with poor prognosis. Due to the high expression of HER2, targeted HER2 agents have been one of the standard therapies for HER2 + breast cancer and have significantly improved the survival prognosis of patients with this type of breast cancer [245–248].

Trastuzumab, as the first humanized HER2 monoclonal antibody, has been widely used in clinical treatment. However, the emergence of drug resistance remains a significant challenge in clinical practice [249]. Du R et al. [250] used scRNA-seq to identify a critical cellular component of drug resistance out of trastuzumab, PDPN+CAF, that CAF induces tumor resistance by secreting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2), which inhibit the killing ability of NK cells against tumor cells. Drug targeting of IDO1 and TDO2 reversed the functional inhibition of NK cells by CAFs, thereby reducing tumor resistance to trastuzumab.

TNBC

Chemotherapy

Compared to other breast cancer subtypes, TNBC lacks available clinical targets, exhibits a high risk of recurrence, and demonstrates a poor prognosis [251, 252]. Chemotherapy serves as the primary systemic treatment for patients with early and advanced TNBC, and many clinical studies have been conducted to explore strategies for improving the efficacy of chemotherapy in TNBC [253–256]. However, the emergence of chemotherapy resistance significantly contributes to clinical treatment failure and poor prognosis, resulting in a 5-year survival rate lower than that of non-TNBC breast cancer [257]. With further research advancements, the mechanism underlying TNBC chemotherapy resistance at single-cell resolution has gradually been elucidated.

Lee et al. [258] applied scRNA-seq to investigate metastatic breast cancer cell lines that were untreated, sensitive to paclitaxel chemotherapy, and resistant to paclitaxel chemotherapy, respectively. This study unveiled the dynamic cellular stress response mechanism under drug stimulation. The findings demonstrated the presence of various specific drug-resistant RNA variants in the drug-resistant cells, which were implicated in microtubule stabilization, cell adhesion, and cell surface signal transduction. Notably, the gene expression profile of the resistant cells resembled that of the untreated cells but exhibited a significant increase in expression abundance. Kim C et al. [259] conducted a longitudinal analysis of 20 patients with TNBC undergoing neoadjuvant chemotherapy (NAC) using scDNA-seq and scRNA-seq. Their findings revealed that the resistance genotype in TNBC was pre-existing and underwent adaptive selection during NAC. Following chemotherapy, TNBC patients exhibited adaptive genomic mutations, copy number aberrations, and drug-resistant phenotypes through transcriptional reprogramming. Therefore, the application of SCS aids in elucidating the mechanism of TNBC drug resistance during NAC, enabling clinicians to timely adjust the NAC regimen for optimal treatment outcomes in TNBC patients. By monitoring cell epigenomics and transcriptomics at single-cell resolution, Marsolier J et al. [260] found that the trimethylation modification of lysine 27 of histone chromatin 3 (H3K27me3) can regulate cell fate at the beginning of chemotherapy. Consumption of H3K27me3 enhanced the potential for chemotherapy tolerance in triple-negative breast cancer cell lines, and using inhibitors to block histone demethylation at this site reduced the number of resistant cells. Therefore, the application of SCS can help to explain the causes of chemotherapy resistance further and indicate the potential for further treatment of drug-resistant TNBC patients.

Immunotherapy

Tumor immunotherapy has revolutionized conventional cancer treatment by harnessing the power of the immune system to combat tumors [261–263]. Immunotherapy has demonstrated significant efficacy in TNBC due to its high immunogenicity and elevated expression levels of immune markers, such as PD-L1 and PD-1 (programmed death 1) [264, 265]. Currently, the primary focus of TNBC immunotherapy research lies in ICB which targets the PD-1/PD-L1 axis. However, although multiple clinical trials have demonstrated that ICB can benefit some patients with TNBC [266–268], the molecular characteristics of non-responders and the effective predictive markers for ICB treatment remain unclear.

Extensive research has been conducted to understand why only some patients respond to ICB and to identify markers that can predict the effectiveness of ICB treatment. Bassez A et al. [269] treated 29 newly diagnosed patients and 11 patients undergoing neoadjuvant chemotherapy with anti-PD-1 antibodies for about ten days. Paired pre- versus on-treatment biopsies were subjected to single-cell transcriptome, T cell receptor and proteome profiling. In pre-treatment biopsies, some cell types with potential contributions to immunotherapy outcomes were identified, particularly the cell subtypes associated with T cell clonal proliferation: immunoregulatory dendritic cells (PD-L1+), specialized macrophages (CCR2+ or MMP9+), and tumor cells expressing MHC-I/II were positively correlated with T cell expansion. In contrast, undifferentiated pro-effector/memory T cells (TCF7+, GZMK+) or inhibitory macrophages (CX3CR1+, C3+) were inversely associated with T cell expansion. Zhang Y et al. [270] analyzed the scRNA-seq results of 11 advanced TNBC patients who received paclitaxel monotherapy and 11 patients who received paclitaxel combined with atezolizumab before and after treatment. They found that CD8+CXCL13+ and CD4+CXCL13+ T cells could be used to predict the effective response to PD-L1 blockade, and B cells were the most prominent immune cells that predicted clinically effective responses to both treatments. In addition, paclitaxel also impaired the expansion of responsive immune cells induced by atezolizumab during combination chemotherapy. Dendritic cells are essential for activating the immune response and influencing the efficacy of tumor immunotherapy [271]. Wu SY et al. [272] delineated dendritic cells in triple-negative breast cancer (TNBC) at single-cell resolution. Within this study, a specific subpopulation of cells, termed "CCL19+ dendritic cells", exhibited a significant positive correlation with favourable responses to TNBC immunotherapy. Moreover, the levels of CCL19 content in both blood and tumors proved to be effective predictors of clinical benefit in patients undergoing anti-PD1 therapy.

The efficacy of tumor immunotherapy is closely associated with CAFs. Kieffer Y et al. [210] verified that ecm-myCAF and TGFβ-myCAF mediated resistance to ICB therapy in i melanoma and non-small cell lung cancer. It is worth exploring in the future whether these CAFs might also influence the efficacy of immunotherapy in breast cancer.

The spatial localization characteristics of cells within the tumor microenvironment have been shown to correlate with the efficacy of immunotherapy [273]. In TNBC, Wang XQ et al. [274] utilized imaging mass cytometry to obtain spatial protein expression profiles of tumor tissues from 279 patients during immunotherapy (before treatment, early treatment, and post treatment), highlighting different efficacy predictors at various treatment stages. Before treatment, the proliferation index of CD8+ TCF1+ T cells and MHCII+ tumor cells were the primary predictors of response, followed by interactions between tumor cells and immune cells (B cells and CD8+ GZMB+ T cells). During treatment, the characteristics of treatment-sensitive and resistant patients were the enrichment of CD8+ GZMB+ T cells and CD15+ tumor cells, respectively. Shiao SL et al. [275] sequenced tumor tissue samples from 50 patients who received pembrolizumab and radiotherapy (27 patients underwent spatial proteomics sequencing, and 34 patients underwent scRNA-seq). The researchers identified two types of patients who were sensitive to immunotherapy: one group had an abundance of immune cells before treatment, while the other group lacked immune cell infiltration before treatment but generated a strong immune response after immunotherapy and radiotherapy. Significant interactions between effector T cells and antigen-presenting macrophages characterized this strong immune response.

Adoptive cell therapy (ACT) is an immunotherapy method in which the immune cells of the patient are modified in vitro and then transfused back into the patient to enhance anti-tumor immunity, including chimeric antigen receptor T cells (CAR-T) therapy, chimeric antigen receptor-engineered natural killing cells (CAR-NK) therapy and dendritic cells vaccines, among others [276]. ACT has shown promising results in the treatment of certain types of tumors [277–279]. CAR-T therapy is progressively being incorporated into clinical trials for validation of its effectiveness in TNBC [280]. Although there is presently no SCS study conducted in cohorts of breast cancer patients undergoing ACT treatment, SCS has exhibited a crucial role in elucidating the mechanism of ACT and identifying effective biomarkers in other tumors [281–284]. In the future, as ACT becomes more established in breast cancer treatment, it is believed that SCS can further optimize its application effectiveness.

Conclusions

The application of SCS and spatial omics has brought about revolutionary changes in breast cancer research. Firstly, understanding the origin of breast cancer is crucial for the prevention, early diagnosis, and treatment of this common cancer. SCS and spatial omics have unveiled a novel perspective on the origin of breast cancer. Secondly, given the high heterogeneity of breast cancer, precise individualized treatment and stratified treatment are of paramount importance. Through analysis at the single cell level, we can gain a more comprehensive and precise understanding of breast cancer heterogeneity. This holds significant implications for personalized treatment, as the cellular heterogeneity of breast cancer may lead to different treatment responses and the development of drug resistance in different patients and at various stages of the disease.

Additionally, tumor metastasis is one of the main reasons leading to poor prognosis for patients. At the resolution of a single cell, we can track the microscopic changes of cells during metastasis, deeply understand the mechanisms that trigger tumor metastasis, and provide guidance for reducing tumor metastasis and improving patient prognosis. However, SCS and spatial omics have some limitations, such as high sequencing costs, sequencing technology noise, and complex data analysis processes. When SCS is not feasible due to various constraints, publicly available single-cell and spatial omics databases can be an alternative resource (Table 1). Although no dedicated database for breast cancer exists, relevant data can be accessed through numerous published literature (Table 2).Table 2 Summary of the publicly published single-cell and spatial omics datasets for normal human breast and breast cancer

Source	Description	Method	Availability	
Nguyen QH et al. [167]	7 samples from healthy breast	scRNA-seq	GSE113197	
Bhat-Nakshatri P et al. [168]	5 samples from healthy breast	scRNA-seq	Correspondence with authors	
Gray GK et al. [169]	16 samples from healthy breast	scRNA-seq	GSE180878	
Pelissier Vatter FA et al. [174]	50 samples from healthy breast	Single-cell mass cytometry	https://doi.org/10.17632/j7mrbgt3hh.1	
HU L et al. [176]	Breast cancer tissues and adjacent or prophylactic normal breast tissues from BRCA1 germline variant carriers (n = 4) and noncarriers (n = 3)	scRNA-seq	Correspondence with authors	
Nee K et al. [177]	BRCA1 germline variant carriers (n = 11) and noncarriers (n = 11)	scRNA-seq	GSE174588	
Reed AD et al. [178]	2.1 million cells from normal breast tissue from 286 individuals	scRNA-seq	E-MTAB-13664	
Navin N et al. [73]	2 breast cancer samples	scDNA-seq	SRA018951	
Karaayvaz M et al. [188]	Breast cancer samples (6 TNBC)	scRNA-seq	GSE118390	
Wu SZ et al. [56]	Breast cancer samples (11 ER + , 5 HER2 + , 10 TNBC)	scRNA-seq	GSE176078	
Liu SQ et al. [190]	Breast cancer samples (2 HR + HER2 +)	scRNA-seq

spatial transcriptomics

	Correspondence with authors	
Savas P et al. [199]	Breast cancer samples (2 TNBC)	scRNA-seq	GSE110686	
Azizi E et al. [200]	Breast cancer samples (5 ER + , 1 HER2 + , 2 TNBC) and matched normal breast tissue, peripheral blood, and lymph node	scRNA-seq	GSE114727

GSE114725

	
Pal B et al. [201]	69 samples encompassing normal breast(n = 24), preneoplastic BRCA1 + /– tissue(n = 4), breast cancer samples (20 ER + , 6 HER2 + , 8 TNBC), and matched lymph node(n = 7)	scRNA-seq	GSE161529	
Wagner J et al. [202]	144 breast cancer samples (54 luminal A, 71 luminal B, 6 luminal B-HER2 + , 1 HER2 + , 6 TNBC) and 50 non-tumor tissue samples	Single-cell mass cytometry	https://data.mendeley.com/datasets/gb83sywsjc/1	
Wang L et al. [205]	Breast cancer samples (5 ER +)	scRNA-seq	GSE248288	
Cords L et al. [208]	14 breast cancer samples (9 ER + , 1 ER + HER2 + , 4 TNBC)	scRNA-seq	https://zenodo.org/records/7540604	
Kieffer Y et al. [210]	8 breast cancer samples	scRNA-seq	EGAS00001004030	
Casasent AK et al. [225]	10 breast cancer samples (4 ER + , 1 ER + HER2 + , 5 TNBC)	TSCS	SRP116771	
Zou Y et al. [227]	6 liver and brain metastases of breast cancer	scRNA-seq	Correspondence with authors	
Liu T et al. [231]	8 breast cancer samples (5 ER + , 3 HER2 +) and matched lymph node metastases	scRNA-seq

spatial transcriptomics

	GSE167036

GSE190811

	
Liu YM et al. [237]	4 breast cancer samples (1 ER + , 2 ER + HER2 + , 1 HER2 +) and matched lymph node metastases	scRNA-seq

spatial transcriptomics

	GSE225600	
Brady SW et al. [243]	4 metastatic ER + breast tumors	scDNA-seq	EGAS00001002436	
Griffiths JI et al. [244]	34 patients with endocrine or CD4/6 inhibitor resistant ER + breast cancer	scRNA-seq	GSE158724	
Du R et al. [250]	6 HER2 + breast cancer samples (3 trastuzumab responders and 3 non-responders)	scRNA-seq	Correspondence with authors	
Kim C et al. [259	4 breast cancer samples (4 TNBC)	scRNA-seq

scDNA-seq

	SRP114962	
Bassez A et al. [269]	Treatment-naive patients treated with pembrolizumab (n = 29) and patients treated with neoadjuvant chemotherapy before receiving pembrolizumab (n = 11)	scRNA-seq

scTCR-seq

	EGAS00001004809	
Zhang Y et al. [270]	22 TNBC patients treated with paclitaxel or its combination with atezolizumab	scRNA-seq

scATAC-seq

	GSE169246	
Wu SY et al. [272]	31 TNBC patients treated with pembrolizumab	scRNA-seq	Correspondence with authors	
Wang XQ et al. [274]	279 TNBC patients treated with pembrolizumab	Imaging mass cytometry	https://zenodo.org/records/7990870	
Shiao SL et al. [275]	50 TNBC patients treated with pembrolizumab	scRNA-seq

scTCR-seq

scBCR-seq

CODEX

	GSE246613

https://doi.org/10.5281/zenodo.10045066

	
Abbreviations: ER estrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, snRNA-seq single-nucleus RNA sequencing, scATAC-seq single-cell assay for transposase-accessible chromatin using sequencing, scTCR-seq single-cell T cell receptor sequencing, scBCR-seq single-cell B cell receptor sequencing, TSCS topographic single cell sequencing, CODEX co-detection by indexing

Future research endeavors should prioritize the development of streamlined and more efficient sequencing protocols and data analysis methodologies while concurrently reducing the associated costs. This will facilitate broader adoption and dissemination of SCS and spatial omics. In addition, how to effectively use these advanced sequencing technologies is also the focus of our future research. For breast cancer, these techniques should be employed to gain a better understanding of gene expression variability and tumor microenvironment complexity in order to identify crucial therapeutic targets. The analysis of the immune microenvironment in milk cancer, for instance, may facilitate the identification of specific immunotherapy strategies and enhance the efficacy of existing treatments. Additionally, in order to advance the personalized treatment of breast cancer patients, it is crucial to leverage SCS and spatial omics technologies for the identification of novel biomarkers.

Overall, the widespread use of SCS and spatial omics in breast cancer research allows us to gain insight into tumor biology and individualized therapy. By analyzing the individual properties of tumors, we can take a critical step toward more precise and effective breast cancer treatment.

Abbreviations

CAFs Cancer-associated fibroblasts

dCAFs Developmental CAFs

CODEX Co-detection by indexing

DR-seq GDNA-mRNA sequencing

ECs Endothelial cells

ER Estrogen receptor

HR Hormone receptor

HER2 Human epidermal growth factor receptor 2

IHC Immunohistochemistry

ICB Immune checkpoint blockade

LIPEC Lipid processing endothelial cell

MHC Major histocompatibility complex

mCAFs Stromal CAFs

PR Progesterone receptor

PD-L1 Programmed death ligand 1

PD-1 Programmed death 1

SCS Single-cell sequencing

scRNA-seq Single-cell RNA sequencing

scDNA-seq Single-cell DNA sequencing

snRNA-seq Single-nucleus RNA sequencing

scATAC-seq Single-cell assay for transposase-accessible chromatin using sequencing scTCR-seqSingle-cell T cell receptor sequencing

scBCR-seq Single-cell B cell receptor sequencing

senCAFs Senescent CAFs

SNARE-seq Single-nucleus chromatin accessibility and mRNA expression sequencing

TAMs Tumor-associated macrophages

TNBC Triple-negative breast cancer

vCAFs Vascular CAFs

Acknowledgements

The figures are created with Biorender.com.

Authors’ contributions

Xin Xiong and Xin Wang conceived and drafted the manuscript and drew the figures and tables. Ke-Da Yu, Cui-Cui Liu and Zhi-Ming Shao discussed the concepts and provided valuable suggestions and revised the manuscript.

Funding

This work was supported by the National Key R&D Program of China (grant number: 2023YFC3404100, 2023YFC2506400), and National Natural Science Foundation of China (grant number: 82325042, 82203860), and Shanghai Municipal Education Commission Scientific Research Innovation Project (grant number: 2023–05-50), Wu Jieping Medical Foundation Research Project (grant number: 32067502023–18-29). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Xin Xiong and Xin Wang contribute equally to this work.
==== Refs
References

1. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
2. Goldhirsch A Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013 Ann Oncol 2013 24 2206 2223 10.1093/annonc/mdt303 23917950
Goldhirsch A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23.23917950
3. Parker JS Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 2009 27 1160 1167 10.1200/JCO.2008.18.1370 19204204
Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.19204204
4. Waks AG Winer EP Breast cancer treatment: a review Jama 2019 321 288 300 10.1001/jama.2018.19323 30667505
Waks AG, Winer EP. Breast cancer treatment: a review. Jama. 2019;321:288–300.30667505
5. Burstein HJ Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 Ann Oncol 2021 32 1216 1235 10.1016/j.annonc.2021.06.023 34242744
Burstein HJ, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216–35.34242744
6. Rozenblatt-Rosen O The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution Cell 2020 181 236 249 10.1016/j.cell.2020.03.053 32302568
Rozenblatt-Rosen O, et al. The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution. Cell. 2020;181:236–49.32302568
7. Ozsolak F Milos PM RNA sequencing: advances, challenges and opportunities Nat Rev Genet 2011 12 87 98 10.1038/nrg2934 21191423
Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12:87–98.21191423
8. Hong M RNA sequencing: new technologies and applications in cancer research J Hematol Oncol 2020 13 166 10.1186/s13045-020-01005-x 33276803
Hong M, et al. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol. 2020;13:166.33276803
9. Gohil SH Iorgulescu JB Braun DA Keskin DB Livak KJ Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy Nat Rev Clin Oncol 2021 18 244 256 10.1038/s41571-020-00449-x 33277626
Gohil SH, Iorgulescu JB, Braun DA, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:244–56.33277626
10. Li X Wang CY From bulk, single-cell to spatial RNA sequencing Int J Oral Sci 2021 13 36 10.1038/s41368-021-00146-0 34782601
Li X, Wang CY. From bulk, single-cell to spatial RNA sequencing. Int J Oral Sci. 2021;13:36.34782601
11. Lei Y Applications of single-cell sequencing in cancer research: progress and perspectives J Hematol Oncol 2021 14 91 10.1186/s13045-021-01105-2 34108022
Lei Y, et al. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol. 2021;14:91.34108022
12. Walsh LA Quail DF Decoding the tumor microenvironment with spatial technologies Nat Immunol 2023 24 1982 1993 10.1038/s41590-023-01678-9 38012408
Walsh LA, Quail DF. Decoding the tumor microenvironment with spatial technologies. Nat Immunol. 2023;24:1982–93.38012408
13. Elhanani O Ben-Uri R Keren L Spatial profiling technologies illuminate the tumor microenvironment Cancer Cell 2023 41 404 420 10.1016/j.ccell.2023.01.010 36800999
Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41:404–20.36800999
14. Tang F mRNA-Seq whole-transcriptome analysis of a single cell Nat Methods 2009 6 377 382 10.1038/nmeth.1315 19349980
Tang F, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6:377–82.19349980
15. No authors listed. Method of the year 2013. Nat Methods. 2014;11:1.
16. No authors listed. Method of the year 2019: single-cell multimodal omics. Nat Methods. 2020;17:1.
17. Van de Sande B Applications of single-cell RNA sequencing in drug discovery and development Nat Rev Drug Discov 2023 22 496 520 10.1038/s41573-023-00688-4 37117846
Van de Sande B, et al. Applications of single-cell RNA sequencing in drug discovery and development. Nat Rev Drug Discov. 2023;22:496–520.37117846
18. Ren X COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas Cell 2021 184 1895 1913.e1819 10.1016/j.cell.2021.01.053 33657410
Ren X, et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell. 2021;184:1895-1913.e1819.33657410
19. Nelms B Walbot V Defining the developmental program leading to meiosis in maize Science 2019 364 52 56 10.1126/science.aav6428 30948545
Nelms B, Walbot V. Defining the developmental program leading to meiosis in maize. Science. 2019;364:52–6.30948545
20. Zhang TQ Chen Y Liu Y Lin WH Wang JW Single-cell transcriptome atlas and chromatin accessibility landscape reveal differentiation trajectories in the rice root Nat Commun 2021 12 2053 10.1038/s41467-021-22352-4 33824350
Zhang TQ, Chen Y, Liu Y, Lin WH, Wang JW. Single-cell transcriptome atlas and chromatin accessibility landscape reveal differentiation trajectories in the rice root. Nat Commun. 2021;12:2053.33824350
21. Karaiskos N The Drosophila embryo at single-cell transcriptome resolution Science 2017 358 194 199 10.1126/science.aan3235 28860209
Karaiskos N, et al. The Drosophila embryo at single-cell transcriptome resolution. Science. 2017;358:194–9.28860209
22. Davie K A single-cell transcriptome atlas of the aging drosophila brain Cell 2018 174 982 998.e920 10.1016/j.cell.2018.05.057 29909982
Davie K, et al. A single-cell transcriptome atlas of the aging drosophila brain. Cell. 2018;174:982-998.e920.29909982
23. Gawad C Koh W Quake SR Single-cell genome sequencing: current state of the science Nat Rev Genet 2016 17 175 188 10.1038/nrg.2015.16 26806412
Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current state of the science. Nat Rev Genet. 2016;17:175–88.26806412
24. Kolodziejczyk AA Kim JK Svensson V Marioni JC Teichmann SA The technology and biology of single-cell RNA sequencing Mol Cell 2015 58 610 620 10.1016/j.molcel.2015.04.005 26000846
Kolodziejczyk AA, Kim JK, Svensson V, Marioni JC, Teichmann SA. The technology and biology of single-cell RNA sequencing. Mol Cell. 2015;58:610–20.26000846
25. Bennett HM Stephenson W Rose CM Darmanis S Single-cell proteomics enabled by next-generation sequencing or mass spectrometry Nat Methods 2023 20 363 374 10.1038/s41592-023-01791-5 36864196
Bennett HM, Stephenson W, Rose CM, Darmanis S. Single-cell proteomics enabled by next-generation sequencing or mass spectrometry. Nat Methods. 2023;20:363–74.36864196
26. Casado-Pelaez M Bueno-Costa A Esteller M Single cell cancer epigenetics Trends Cancer 2022 8 820 838 10.1016/j.trecan.2022.06.005 35821003
Casado-Pelaez M, Bueno-Costa A, Esteller M. Single cell cancer epigenetics. Trends Cancer. 2022;8:820–38.35821003
27. Zenobi R Single-cell metabolomics: analytical and biological perspectives Science 2013 342 1243259 10.1126/science.1243259 24311695
Zenobi R. Single-cell metabolomics: analytical and biological perspectives. Science. 2013;342:1243259.24311695
28. Vandereyken K Sifrim A Thienpont B Voet T Methods and applications for single-cell and spatial multi-omics Nat Rev Genet 2023 24 494 515 10.1038/s41576-023-00580-2 36864178
Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023;24:494–515.36864178
29. Xue R Liver tumour immune microenvironment subtypes and neutrophil heterogeneity Nature 2022 612 141 147 10.1038/s41586-022-05400-x 36352227
Xue R, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612:141–7.36352227
30. Wang L Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment Gut 2023 72 958 971 10.1136/gutjnl-2021-326070 35688610
Wang L, et al. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut. 2023;72:958–71.35688610
31. Huang D Advances in single-cell RNA sequencing and its applications in cancer research J Hematol Oncol 2023 16 98 10.1186/s13045-023-01494-6 37612741
Huang D, et al. Advances in single-cell RNA sequencing and its applications in cancer research. J Hematol Oncol. 2023;16:98.37612741
32. Lim J Transitioning single-cell genomics into the clinic Nat Rev Genet 2023 24 573 584 10.1038/s41576-023-00613-w 37258725
Lim J, et al. Transitioning single-cell genomics into the clinic. Nat Rev Genet. 2023;24:573–84.37258725
33. Wu Y Zhang K Tools for the analysis of high-dimensional single-cell RNA sequencing data Nat Rev Nephrol 2020 16 408 421 10.1038/s41581-020-0262-0 32221477
Wu Y, Zhang K. Tools for the analysis of high-dimensional single-cell RNA sequencing data. Nat Rev Nephrol. 2020;16:408–21.32221477
34. Satija R Farrell JA Gennert D Schier AF Regev A Spatial reconstruction of single-cell gene expression data Nat Biotechnol 2015 33 495 502 10.1038/nbt.3192 25867923
Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495–502.25867923
35. Wolf FA Angerer P Theis FJ SCANPY: large-scale single-cell gene expression data analysis Genome Biol 2018 19 15 10.1186/s13059-017-1382-0 29409532
Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19:15.29409532
36. Cao J The single-cell transcriptional landscape of mammalian organogenesis Nature 2019 566 496 502 10.1038/s41586-019-0969-x 30787437
Cao J, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566:496–502.30787437
37. Jin S Inference and analysis of cell-cell communication using Cell Chat Nat Commun 2021 12 1088 10.1038/s41467-021-21246-9 33597522
Jin S, et al. Inference and analysis of cell-cell communication using Cell Chat. Nat Commun. 2021;12:1088.33597522
38. Aibar S SCENIC: single-cell regulatory network inference and clustering Nat Methods 2017 14 1083 1086 10.1038/nmeth.4463 28991892
Aibar S, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14:1083–6.28991892
39. Liu Y Beyer A Aebersold R On the dependency of cellular protein levels on mRNA abundance Cell 2016 165 535 550 10.1016/j.cell.2016.03.014 27104977
Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016;165:535–50.27104977
40. Vogel C Marcotte EM Insights into the regulation of protein abundance from proteomic and transcriptomic analyses Nat Rev Genet 2012 13 227 232 10.1038/nrg3185 22411467
Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227–32.22411467
41. Dey SS Kester L Spanjaard B Bienko M van Oudenaarden A Integrated genome and transcriptome sequencing of the same cell Nat Biotechnol 2015 33 285 289 10.1038/nbt.3129 25599178
Dey SS, Kester L, Spanjaard B, Bienko M, van Oudenaarden A. Integrated genome and transcriptome sequencing of the same cell. Nat Biotechnol. 2015;33:285–9.25599178
42. Chen S Lake BB Zhang K High-throughput sequencing of the transcriptome and chromatin accessibility in the same cell Nat Biotechnol 2019 37 1452 1457 10.1038/s41587-019-0290-0 31611697
Chen S, Lake BB, Zhang K. High-throughput sequencing of the transcriptome and chromatin accessibility in the same cell. Nat Biotechnol. 2019;37:1452–7.31611697
43. Zhan T Rindtorff N Betge J Ebert MP Boutros M CRISPR/Cas9 for cancer research and therapy Semin Cancer Biol 2019 55 106 119 10.1016/j.semcancer.2018.04.001 29673923
Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M. CRISPR/Cas9 for cancer research and therapy. Semin Cancer Biol. 2019;55:106–19.29673923
44. Katti A Diaz BJ Caragine CM Sanjana NE Dow LE CRISPR in cancer biology and therapy Nat Rev Cancer 2022 22 259 279 10.1038/s41568-022-00441-w 35194172
Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22:259–79.35194172
45. Cheng J Massively parallel CRISPR-based genetic perturbation screening at single-cell resolution Adv Sci (Weinh) 2023 10 e2204484 10.1002/advs.202204484 36504444
Cheng J, et al. Massively parallel CRISPR-based genetic perturbation screening at single-cell resolution. Adv Sci (Weinh). 2023;10:e2204484.36504444
46. Jaitin DA Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-Seq Cell 2016 167 1883 1896.e1815 10.1016/j.cell.2016.11.039 27984734
Jaitin DA, et al. Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-Seq. Cell. 2016;167:1883-1896.e1815.27984734
47. Dixit A Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens Cell 2016 167 1853 1866.e1817 10.1016/j.cell.2016.11.038 27984732
Dixit A, et al. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell. 2016;167:1853-1866.e1817.27984732
48. Zhou P Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer Nature 2023 624 154 163 10.1038/s41586-023-06733-x 37968405
Zhou P, et al. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature. 2023;624:154–63.37968405
49. Marx V Method of the year: spatially resolved transcriptomics Nat Methods 2021 18 9 14 10.1038/s41592-020-01033-y 33408395
Marx V. Method of the year: spatially resolved transcriptomics. Nat Methods. 2021;18:9–14.33408395
50. Alexandrov T Saez-Rodriguez J Saka SK Enablers and challenges of spatial omics, a melting pot of technologies Mol Syst Biol 2023 19 e10571 10.15252/msb.202110571 37842805
Alexandrov T, Saez-Rodriguez J, Saka SK. Enablers and challenges of spatial omics, a melting pot of technologies. Mol Syst Biol. 2023;19:e10571.37842805
51. Bressan D Battistoni G Hannon GJ The dawn of spatial omics Science 2023 381 eabq4964 10.1126/science.abq4964 37535749
Bressan D, Battistoni G, Hannon GJ. The dawn of spatial omics. Science. 2023;381:eabq4964.37535749
52. Chen A Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays Cell 2022 185 1777 1792.e1721 10.1016/j.cell.2022.04.003 35512705
Chen A, et al. Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays. Cell. 2022;185:1777-1792.e1721.35512705
53. Goltsev Y Deep profiling of mouse splenic architecture with CODEX multiplexed imaging Cell 2018 174 968 981.e915 10.1016/j.cell.2018.07.010 30078711
Goltsev Y, et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell. 2018;174:968-981.e915.30078711
54. Rao A Barkley D França GS Yanai I Exploring tissue architecture using spatial transcriptomics Nature 2021 596 211 220 10.1038/s41586-021-03634-9 34381231
Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596:211–20.34381231
55. Longo SK Guo MG Ji AL Khavari PA Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics Nat Rev Genet 2021 22 627 644 10.1038/s41576-021-00370-8 34145435
Longo SK, Guo MG, Ji AL, Khavari PA. Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. Nat Rev Genet. 2021;22:627–44.34145435
56. Wu SZ A single-cell and spatially resolved atlas of human breast cancers Nat Genet 2021 53 1334 1347 10.1038/s41588-021-00911-1 34493872
Wu SZ, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53:1334–47.34493872
57. Sun Y Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma Cancer Cell 2024 42 135 156.e117 10.1016/j.ccell.2023.11.010 38101410
Sun Y, et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell. 2024;42:135-156.e117.38101410
58. Li R Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis Gut 2024 73 470 484 38050068
Li R, et al. Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis. Gut. 2024;73:470–84.38050068
59. Li R Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer Cancer Cell 2022 40 1583 1599.e1510 10.1016/j.ccell.2022.11.001 36423636
Li R, et al. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell. 2022;40:1583-1599.e1510.36423636
60. Lundberg E Borner GHH Spatial proteomics: a powerful discovery tool for cell biology Nat Rev Mol Cell Biol 2019 20 285 302 10.1038/s41580-018-0094-y 30659282
Lundberg E, Borner GHH. Spatial proteomics: a powerful discovery tool for cell biology. Nat Rev Mol Cell Biol. 2019;20:285–302.30659282
61. Black S CODEX multiplexed tissue imaging with DNA-conjugated antibodies Nat Protoc 2021 16 3802 3835 10.1038/s41596-021-00556-8 34215862
Black S, et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc. 2021;16:3802–35.34215862
62. Eckert MA Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts Nature 2019 569 723 728 10.1038/s41586-019-1173-8 31043742
Eckert MA, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569:723–8.31043742
63. Burdett NL Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer Nat Genet 2023 55 437 450 10.1038/s41588-023-01320-2 36849657
Burdett NL, et al. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat Genet. 2023;55:437–50.36849657
64. Fan J Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance Nat Genet 2023 55 2175 2188 10.1038/s41588-023-01570-0 37985817
Fan J, et al. Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance. Nat Genet. 2023;55:2175–88.37985817
65. Duhamel M Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival Nat Commun 2022 13 6665 10.1038/s41467-022-34208-6 36333286
Duhamel M, et al. Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. Nat Commun. 2022;13:6665.36333286
66. Koppenol WH Bounds PL Dang CV Otto Warburg's contributions to current concepts of cancer metabolism Nat Rev Cancer 2011 11 325 337 10.1038/nrc3038 21508971
Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–37.21508971
67. Martínez-Reyes I Chandel NS Cancer metabolism: looking forward Nat Rev Cancer 2021 21 669 680 10.1038/s41568-021-00378-6 34272515
Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669–80.34272515
68. DeBerardinis RJ Keshari KR Metabolic analysis as a driver for discovery, diagnosis, and therapy Cell 2022 185 2678 2689 10.1016/j.cell.2022.06.029 35839759
DeBerardinis RJ, Keshari KR. Metabolic analysis as a driver for discovery, diagnosis, and therapy. Cell. 2022;185:2678–89.35839759
69. Alexandrov T Spatial metabolomics: from a niche field towards a driver of innovation Nat Metab 2023 5 1443 1445 10.1038/s42255-023-00881-0 37679554
Alexandrov T. Spatial metabolomics: from a niche field towards a driver of innovation. Nat Metab. 2023;5:1443–5.37679554
70. Santos AA Spatial metabolomics and its application in the liver Hepatology 2024 79 1158 1179 10.1097/HEP.0000000000000341 36811413
Santos AA, et al. Spatial metabolomics and its application in the liver. Hepatology. 2024;79:1158–79.36811413
71. Tang R Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response Cell Rep Med 2023 4 101234 10.1016/j.xcrm.2023.101234 37852179
Tang R, et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Rep Med. 2023;4:101234.37852179
72. Randall EC Localized metabolomic gradients in patient-derived xenograft models of glioblastoma Cancer Res 2020 80 1258 1267 10.1158/0008-5472.CAN-19-0638 31767628
Randall EC, et al. Localized metabolomic gradients in patient-derived xenograft models of glioblastoma. Cancer Res. 2020;80:1258–67.31767628
73. Navin N Tumour evolution inferred by single-cell sequencing Nature 2011 472 90 94 10.1038/nature09807 21399628
Navin N, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–4.21399628
74. Zong C Lu S Chapman AR Xie XS Genome-wide detection of single-nucleotide and copy-number variations of a single human cell Science 2012 338 1622 1626 10.1126/science.1229164 23258894
Zong C, Lu S, Chapman AR, Xie XS. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science. 2012;338:1622–6.23258894
75. Gole J Massively parallel polymerase cloning and genome sequencing of single cells using nanoliter microwells Nat Biotechnol 2013 31 1126 1132 10.1038/nbt.2720 24213699
Gole J, et al. Massively parallel polymerase cloning and genome sequencing of single cells using nanoliter microwells. Nat Biotechnol. 2013;31:1126–32.24213699
76. Fan X SMOOTH-seq: single-cell genome sequencing of human cells on a third-generation sequencing platform Genome Biol 2021 22 195 10.1186/s13059-021-02406-y 34193237
Fan X, et al. SMOOTH-seq: single-cell genome sequencing of human cells on a third-generation sequencing platform. Genome Biol. 2021;22:195.34193237
77. Nagano T Single-cell Hi-C reveals cell-to-cell variability in chromosome structure Nature 2013 502 59 64 10.1038/nature12593 24067610
Nagano T, et al. Single-cell Hi-C reveals cell-to-cell variability in chromosome structure. Nature. 2013;502:59–64.24067610
78. Farlik M Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics Cell Rep 2015 10 1386 1397 10.1016/j.celrep.2015.02.001 25732828
Farlik M, et al. Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics. Cell Rep. 2015;10:1386–97.25732828
79. Buenrostro JD Single-cell chromatin accessibility reveals principles of regulatory variation Nature 2015 523 486 490 10.1038/nature14590 26083756
Buenrostro JD, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2015;523:486–90.26083756
80. Rotem A Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state Nat Biotechnol 2015 33 1165 1172 10.1038/nbt.3383 26458175
Rotem A, et al. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat Biotechnol. 2015;33:1165–72.26458175
81. Pixberg CF Analysis of DNA methylation in single circulating tumor cells Oncogene 2017 36 3223 3231 10.1038/onc.2016.480 28068321
Pixberg CF, et al. Analysis of DNA methylation in single circulating tumor cells. Oncogene. 2017;36:3223–31.28068321
82. Harada A A chromatin integration labelling method enables epigenomic profiling with lower input Nat Cell Biol 2019 21 287 296 10.1038/s41556-018-0248-3 30532068
Harada A, et al. A chromatin integration labelling method enables epigenomic profiling with lower input. Nat Cell Biol. 2019;21:287–96.30532068
83. Bartosovic M Kabbe M Castelo-Branco G Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues Nat Biotechnol 2021 39 825 835 10.1038/s41587-021-00869-9 33846645
Bartosovic M, Kabbe M, Castelo-Branco G. Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues. Nat Biotechnol. 2021;39:825–35.33846645
84. Shareef SJ Extended-representation bisulfite sequencing of gene regulatory elements in multiplexed samples and single cells Nat Biotechnol 2021 39 1086 1094 10.1038/s41587-021-00910-x 33958785
Shareef SJ, et al. Extended-representation bisulfite sequencing of gene regulatory elements in multiplexed samples and single cells. Nat Biotechnol. 2021;39:1086–94.33958785
85. Hunt KV scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs Sci Rep 2022 12 5776 10.1038/s41598-022-09765-x 35388081
Hunt KV, et al. scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs. Sci Rep. 2022;12:5776.35388081
86. Islam S Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq Genome Res 2011 21 1160 1167 10.1101/gr.110882.110 21543516
Islam S, et al. Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome Res. 2011;21:1160–7.21543516
87. Ramsköld D Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells Nat Biotechnol 2012 30 777 782 10.1038/nbt.2282 22820318
Ramsköld D, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol. 2012;30:777–82.22820318
88. Sasagawa Y Quartz-Seq: a highly reproducible and sensitive single-cell RNA sequencing method, reveals non-genetic gene-expression heterogeneity Genome Biol 2013 14 R31 10.1186/gb-2013-14-4-r31 23594475
Sasagawa Y, et al. Quartz-Seq: a highly reproducible and sensitive single-cell RNA sequencing method, reveals non-genetic gene-expression heterogeneity. Genome Biol. 2013;14:R31.23594475
89. Picelli S Smart-seq2 for sensitive full-length transcriptome profiling in single cells Nat Methods 2013 10 1096 1098 10.1038/nmeth.2639 24056875
Picelli S, et al. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods. 2013;10:1096–8.24056875
90. Jaitin DA Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types Science 2014 343 776 779 10.1126/science.1247651 24531970
Jaitin DA, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science. 2014;343:776–9.24531970
91. Macosko EZ Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets Cell 2015 161 1202 1214 10.1016/j.cell.2015.05.002 26000488
Macosko EZ, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202–14.26000488
92. Klein AM Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells Cell 2015 161 1187 1201 10.1016/j.cell.2015.04.044 26000487
Klein AM, et al. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell. 2015;161:1187–201.26000487
93. Gierahn TM Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput Nat Methods 2017 14 395 398 10.1038/nmeth.4179 28192419
Gierahn TM, et al. Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. Nat Methods. 2017;14:395–8.28192419
94. Gupta I, et al. Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells. Nat Biotechnol. 2018;36:1197–1200.
95. Shi ZX High-throughput and high-accuracy single-cell RNA isoform analysis using PacBio circular consensus sequencing Nat Commun 2023 14 2631 10.1038/s41467-023-38324-9 37149708
Shi ZX, et al. High-throughput and high-accuracy single-cell RNA isoform analysis using PacBio circular consensus sequencing. Nat Commun. 2023;14:2631.37149708
96. Al'Khafaji AM High-throughput RNA isoform sequencing using programmed cDNA concatenation Nat Biotechnol 2024 42 582 586 10.1038/s41587-023-01815-7 37291427
Al’Khafaji AM, et al. High-throughput RNA isoform sequencing using programmed cDNA concatenation. Nat Biotechnol. 2024;42:582–6.37291427
97. Bendall SC Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum Science 2011 332 687 696 10.1126/science.1198704 21551058
Bendall SC, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332:687–96.21551058
98. Hughes AJ Single-cell western blotting Nat Methods 2014 11 749 755 10.1038/nmeth.2992 24880876
Hughes AJ, et al. Single-cell western blotting. Nat Methods. 2014;11:749–55.24880876
99. Darmanis S Simultaneous multiplexed measurement of RNA and proteins in single cells Cell Rep 2016 14 380 389 10.1016/j.celrep.2015.12.021 26748716
Darmanis S, et al. Simultaneous multiplexed measurement of RNA and proteins in single cells. Cell Rep. 2016;14:380–9.26748716
100. Shahi P Kim SC Haliburton JR Gartner ZJ Abate AR Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding Sci Rep 2017 7 44447 10.1038/srep44447 28290550
Shahi P, Kim SC, Haliburton JR, Gartner ZJ, Abate AR. Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding. Sci Rep. 2017;7:44447.28290550
101. Zhu Y Nanodroplet processing platform for deep and quantitative proteome profiling of 10–100 mammalian cells Nat Commun 2018 9 882 10.1038/s41467-018-03367-w 29491378
Zhu Y, et al. Nanodroplet processing platform for deep and quantitative proteome profiling of 10–100 mammalian cells. Nat Commun. 2018;9:882.29491378
102. Budnik B Levy E Harmange G Slavov N SCoPE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation Genome Biol 2018 19 161 10.1186/s13059-018-1547-5 30343672
Budnik B, Levy E, Harmange G, Slavov N. SCoPE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation. Genome Biol. 2018;19:161.30343672
103. Zhu Y, et al. Single-cell proteomics reveals changes in expression during hair-cell development. Elife. 2019;8:e50777.
104. Amantonico A Urban PL Fagerer SR Balabin RM Zenobi R Single-cell MALDI-MS as an analytical tool for studying intrapopulation metabolic heterogeneity of unicellular organisms Anal Chem 2010 82 7394 7400 10.1021/ac1015326 20707357
Amantonico A, Urban PL, Fagerer SR, Balabin RM, Zenobi R. Single-cell MALDI-MS as an analytical tool for studying intrapopulation metabolic heterogeneity of unicellular organisms. Anal Chem. 2010;82:7394–400.20707357
105. Gong X Single cell analysis with probe ESI-mass spectrometry: detection of metabolites at cellular and subcellular levels Anal Chem 2014 86 3809 3816 10.1021/ac500882e 24641101
Gong X, et al. Single cell analysis with probe ESI-mass spectrometry: detection of metabolites at cellular and subcellular levels. Anal Chem. 2014;86:3809–16.24641101
106. Zhu H Single-neuron identification of chemical constituents, physiological changes, and metabolism using mass spectrometry Proc Natl Acad Sci U S A 2017 114 2586 2591 10.1073/pnas.1615557114 28223513
Zhu H, et al. Single-neuron identification of chemical constituents, physiological changes, and metabolism using mass spectrometry. Proc Natl Acad Sci U S A. 2017;114:2586–91.28223513
107. Liu R Pan N Zhu Y Yang Z T-Probe: an integrated microscale device for online in situ single cell analysis and metabolic profiling using mass spectrometry Anal Chem 2018 90 11078 11085 10.1021/acs.analchem.8b02927 30119596
Liu R, Pan N, Zhu Y, Yang Z. T-Probe: an integrated microscale device for online in situ single cell analysis and metabolic profiling using mass spectrometry. Anal Chem. 2018;90:11078–85.30119596
108. Yin R Burnum-Johnson KE Sun X Dey SK Laskin J High spatial resolution imaging of biological tissues using nanospray desorption electrospray ionization mass spectrometry Nat Protoc 2019 14 3445 3470 10.1038/s41596-019-0237-4 31723300
Yin R, Burnum-Johnson KE, Sun X, Dey SK, Laskin J. High spatial resolution imaging of biological tissues using nanospray desorption electrospray ionization mass spectrometry. Nat Protoc. 2019;14:3445–70.31723300
109. Thomen A Subcellular mass spectrometry imaging and absolute quantitative analysis across organelles ACS Nano 2020 14 4316 4325 10.1021/acsnano.9b09804 32239916
Thomen A, et al. Subcellular mass spectrometry imaging and absolute quantitative analysis across organelles. ACS Nano. 2020;14:4316–25.32239916
110. Angermueller C Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity Nat Methods 2016 13 229 232 10.1038/nmeth.3728 26752769
Angermueller C, et al. Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity. Nat Methods. 2016;13:229–32.26752769
111. Hou Y Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas Cell Res 2016 26 304 319 10.1038/cr.2016.23 26902283
Hou Y, et al. Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas. Cell Res. 2016;26:304–19.26902283
112. Cheow LF Single-cell multimodal profiling reveals cellular epigenetic heterogeneity Nat Methods 2016 13 833 836 10.1038/nmeth.3961 27525975
Cheow LF, et al. Single-cell multimodal profiling reveals cellular epigenetic heterogeneity. Nat Methods. 2016;13:833–6.27525975
113. Macaulay IC Separation and parallel sequencing of the genomes and transcriptomes of single cells using G&T-seq Nat Protoc 2016 11 2081 2103 10.1038/nprot.2016.138 27685099
Macaulay IC, et al. Separation and parallel sequencing of the genomes and transcriptomes of single cells using G&T-seq. Nat Protoc. 2016;11:2081–103.27685099
114. Pott S. Simultaneous measurement of chromatin accessibility, DNA methylation, and nucleosome phasing in single cells. Elife. 2017;6:e23203.
115. Stoeckius M Simultaneous epitope and transcriptome measurement in single cells Nat Methods 2017 14 865 868 10.1038/nmeth.4380 28759029
Stoeckius M, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14:865–8.28759029
116. Han KY SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells Genome Res 2018 28 75 87 10.1101/gr.223263.117 29208629
Han KY, et al. SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells. Genome Res. 2018;28:75–87.29208629
117. Clark SJ scNMT-seq enables joint profiling of chromatin accessibility DNA methylation and transcription in single cells Nat Commun 2018 9 781 10.1038/s41467-018-03149-4 29472610
Clark SJ, et al. scNMT-seq enables joint profiling of chromatin accessibility DNA methylation and transcription in single cells. Nat Commun. 2018;9:781.29472610
118. Liu L Deconvolution of single-cell multi-omics layers reveals regulatory heterogeneity Nat Commun 2019 10 470 10.1038/s41467-018-08205-7 30692544
Liu L, et al. Deconvolution of single-cell multi-omics layers reveals regulatory heterogeneity. Nat Commun. 2019;10:470.30692544
119. Rodriguez-Meira A Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing Mol Cell 2019 73 1292 1305.e1298 10.1016/j.molcel.2019.01.009 30765193
Rodriguez-Meira A, et al. Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Mol Cell. 2019;73:1292-1305.e1298.30765193
120. Gaiti F Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia Nature 2019 569 576 580 10.1038/s41586-019-1198-z 31092926
Gaiti F, et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019;569:576–80.31092926
121. Rooijers K Simultaneous quantification of protein-DNA contacts and transcriptomes in single cells Nat Biotechnol 2019 37 766 772 10.1038/s41587-019-0150-y 31209373
Rooijers K, et al. Simultaneous quantification of protein-DNA contacts and transcriptomes in single cells. Nat Biotechnol. 2019;37:766–72.31209373
122. Zachariadis V Cheng H Andrews N Enge M A highly scalable method for joint whole-genome sequencing and gene-expression profiling of single cells Mol Cell 2020 80 541 553.e545 10.1016/j.molcel.2020.09.025 33068522
Zachariadis V, Cheng H, Andrews N, Enge M. A highly scalable method for joint whole-genome sequencing and gene-expression profiling of single cells. Mol Cell. 2020;80:541-553.e545.33068522
123. Ma S Chromatin potential identified by shared single-cell profiling of RNA and chromatin Cell 2020 183 1103 1116.e1120 10.1016/j.cell.2020.09.056 33098772
Ma S, et al. Chromatin potential identified by shared single-cell profiling of RNA and chromatin. Cell. 2020;183:1103-1116.e1120.33098772
124. Tan L Changes in genome architecture and transcriptional dynamics progress independently of sensory experience during post-natal brain development Cell 2021 184 741 758.e717 10.1016/j.cell.2020.12.032 33484631
Tan L, et al. Changes in genome architecture and transcriptional dynamics progress independently of sensory experience during post-natal brain development. Cell. 2021;184:741-758.e717.33484631
125. Chen AF NEAT-seq: simultaneous profiling of intra-nuclear proteins, chromatin accessibility and gene expression in single cells Nat Methods 2022 19 547 553 10.1038/s41592-022-01461-y 35501385
Chen AF, et al. NEAT-seq: simultaneous profiling of intra-nuclear proteins, chromatin accessibility and gene expression in single cells. Nat Methods. 2022;19:547–53.35501385
126. Zhang B Characterizing cellular heterogeneity in chromatin state with scCUT&Tag-pro Nat Biotechnol 2022 40 1220 1230 10.1038/s41587-022-01250-0 35332340
Zhang B, et al. Characterizing cellular heterogeneity in chromatin state with scCUT&Tag-pro. Nat Biotechnol. 2022;40:1220–30.35332340
127. Yu L scONE-seq: A single-cell multi-omics method enables simultaneous dissection of phenotype and genotype heterogeneity from frozen tumors Sci Adv 2023 9 eabp8901 10.1126/sciadv.abp8901 36598983
Yu L, et al. scONE-seq: A single-cell multi-omics method enables simultaneous dissection of phenotype and genotype heterogeneity from frozen tumors. Sci Adv. 2023;9:eabp8901.36598983
128. Ke R In situ sequencing for RNA analysis in preserved tissue and cells Nat Methods 2013 10 857 860 10.1038/nmeth.2563 23852452
Ke R, et al. In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods. 2013;10:857–60.23852452
129. Angelo M Multiplexed ion beam imaging of human breast tumors Nat Med 2014 20 436 442 10.1038/nm.3488 24584119
Angelo M, et al. Multiplexed ion beam imaging of human breast tumors. Nat Med. 2014;20:436–42.24584119
130. Lee JH Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues Nat Protoc 2015 10 442 458 10.1038/nprot.2014.191 25675209
Lee JH, et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat Protoc. 2015;10:442–58.25675209
131. Chen KH Boettiger AN Moffitt JR Wang S Zhuang X RNA imaging Spatially resolved, highly multiplexed RNA profiling in single cells Science 2015 348 aaa6090 10.1126/science.aaa6090 25858977
Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. RNA imaging Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015;348:aaa6090.25858977
132. Shah S Lubeck E Zhou W Cai L In situ transcription profiling of single cells reveals spatial organization of cells in the mouse hippocampus Neuron 2016 92 342 357 10.1016/j.neuron.2016.10.001 27764670
Shah S, Lubeck E, Zhou W, Cai L. In situ transcription profiling of single cells reveals spatial organization of cells in the mouse hippocampus. Neuron. 2016;92:342–57.27764670
133. Ståhl PL Visualization and analysis of gene expression in tissue sections by spatial transcriptomics Science 2016 353 78 82 10.1126/science.aaf2403 27365449
Ståhl PL, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353:78–82.27365449
134. Chen J Spatial transcriptomic analysis of cryosectioned tissue samples with Geo-seq Nat Protoc 2017 12 566 580 10.1038/nprot.2017.003 28207000
Chen J, et al. Spatial transcriptomic analysis of cryosectioned tissue samples with Geo-seq. Nat Protoc. 2017;12:566–80.28207000
135. Wang X, et al. Three-dimensional intact-tissue sequencing of single-cell transcriptional states. Science. 2018;361:eaat5691.
136. Rodriques SG Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution Science 2019 363 1463 1467 10.1126/science.aaw1219 30923225
Rodriques SG, et al. Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363:1463–7.30923225
137. Eng CL Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH Nature 2019 568 235 239 10.1038/s41586-019-1049-y 30911168
Eng CL, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019;568:235–9.30911168
138. Vickovic S High-definition spatial transcriptomics for in situ tissue profiling Nat Methods 2019 16 987 990 10.1038/s41592-019-0548-y 31501547
Vickovic S, et al. High-definition spatial transcriptomics for in situ tissue profiling. Nat Methods. 2019;16:987–90.31501547
139. Merritt CR Multiplex digital spatial profiling of proteins and RNA in fixed tissue Nat Biotechnol 2020 38 586 599 10.1038/s41587-020-0472-9 32393914
Merritt CR, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38:586–99.32393914
140. Thornton CA Spatially mapped single-cell chromatin accessibility Nat Commun 2021 12 1274 10.1038/s41467-021-21515-7 33627658
Thornton CA, et al. Spatially mapped single-cell chromatin accessibility. Nat Commun. 2021;12:1274.33627658
141. Deng Y Spatial-CUT&Tag: Spatially resolved chromatin modification profiling at the cellular level Science 2022 375 681 686 10.1126/science.abg7216 35143307
Deng Y, et al. Spatial-CUT&Tag: Spatially resolved chromatin modification profiling at the cellular level. Science. 2022;375:681–6.35143307
142. Zeng H Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer's disease Nat Neurosci 2023 26 430 446 36732642
Zeng H, et al. Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer’s disease. Nat Neurosci. 2023;26:430–46.36732642
143. Barrett T NCBI GEO: archive for functional genomics data sets–update Nucleic Acids Res 2013 41 D991 995 10.1093/nar/gks1193 23193258
Barrett T, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991-995.23193258
144. Regev A, et al. The Human Cell Atlas. Elife. 2017;6:e27041.
145. Hu C Cell Marker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data Nucleic Acids Res 2023 51 D870 d876 10.1093/nar/gkac947 36300619
Hu C, et al. Cell Marker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 2023;51:D870-d876.36300619
146. Zheng LL, et al. ColorCells: a database of expression, classification and functions of lncRNAs in single cells. Brief Bioinform.  2021;22:bbaa325.
147. Han X Construction of a human cell landscape at single-cell level Nature 2020 581 303 309 10.1038/s41586-020-2157-4 32214235
Han X, et al. Construction of a human cell landscape at single-cell level. Nature. 2020;581:303–9.32214235
148. Han X Mapping the Mouse Cell Atlas by Microwell-Seq Cell 2018 172 1091 1107.e1017 10.1016/j.cell.2018.02.001 29474909
Han X, et al. Mapping the Mouse Cell Atlas by Microwell-Seq. Cell. 2018;172:1091-1107.e1017.29474909
149. Zhang Y scTPA: a web tool for single-cell transcriptome analysis of pathway activation signatures Bioinformatics 2020 36 4217 4219 10.1093/bioinformatics/btaa532 32437538
Zhang Y, et al. scTPA: a web tool for single-cell transcriptome analysis of pathway activation signatures. Bioinformatics. 2020;36:4217–9.32437538
150. Sun D TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment Nucleic Acids Res 2021 49 D1420 d1430 10.1093/nar/gkaa1020 33179754
Sun D, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49:D1420-d1430.33179754
151. Wang F SPDB: a comprehensive resource and knowledgebase for proteomic data at the single-cell resolution Nucleic Acids Res 2024 52 D562 d571 10.1093/nar/gkad1018 37953313
Wang F, et al. SPDB: a comprehensive resource and knowledgebase for proteomic data at the single-cell resolution. Nucleic Acids Res. 2024;52:D562-d571.37953313
152. Yuan Z SODB facilitates comprehensive exploration of spatial omics data Nat Methods 2023 20 387 399 10.1038/s41592-023-01773-7 36797409
Yuan Z, et al. SODB facilitates comprehensive exploration of spatial omics data. Nat Methods. 2023;20:387–99.36797409
153. Bagger FO Kinalis S Rapin N BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles Nucleic Acids Res 2019 47 D881 d885 10.1093/nar/gky1076 30395307
Bagger FO, Kinalis S, Rapin N. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res. 2019;47:D881-d885.30395307
154. Fan Z SPASCER: spatial transcriptomics annotation at single-cell resolution Nucleic Acids Res 2023 51 D1138 d1149 10.1093/nar/gkac889 36243975
Fan Z, et al. SPASCER: spatial transcriptomics annotation at single-cell resolution. Nucleic Acids Res. 2023;51:D1138-d1149.36243975
155. Abugessaisa I SCPortalen: human and mouse single-cell centric database Nucleic Acids Res 2018 46 D781 d787 10.1093/nar/gkx949 29045713
Abugessaisa I, et al. SCPortalen: human and mouse single-cell centric database. Nucleic Acids Res. 2018;46:D781-d787.29045713
156. Fan Z Chen R Chen X SpatialDB: a database for spatially resolved transcriptomes Nucleic Acids Res 2020 48 D233 d237 31713629
Fan Z, Chen R, Chen X. SpatialDB: a database for spatially resolved transcriptomes. Nucleic Acids Res. 2020;48:D233-d237.31713629
157. Xu Z STOmicsDB: a comprehensive database for spatial transcriptomics data sharing, analysis and visualization Nucleic Acids Res 2024 52 D1053 d1061 10.1093/nar/gkad933 37953328
Xu Z, et al. STOmicsDB: a comprehensive database for spatial transcriptomics data sharing, analysis and visualization. Nucleic Acids Res. 2024;52:D1053-d1061.37953328
158. Schaum N, et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature. 2018;562:367–72.
159. Franzén O, Gan LM, Björkegren JLM. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database (Oxford). 2019;2019:baz046.
160. Ner-Gaon H Melchior A Golan N Ben-Haim Y Shay T JingleBells: a repository of immune-related single-cell rna-sequencing datasets J Immunol 2017 198 3375 3379 10.4049/jimmunol.1700272 28416714
Ner-Gaon H, Melchior A, Golan N, Ben-Haim Y, Shay T. JingleBells: a repository of immune-related single-cell rna-sequencing datasets. J Immunol. 2017;198:3375–9.28416714
161. Cao ZJ Wei L Lu S Yang DC Gao G Searching large-scale scRNA-seq databases via unbiased cell embedding with Cell BLAST Nat Commun 2020 11 3458 10.1038/s41467-020-17281-7 32651388
Cao ZJ, Wei L, Lu S, Yang DC, Gao G. Searching large-scale scRNA-seq databases via unbiased cell embedding with Cell BLAST. Nat Commun. 2020;11:3458.32651388
162. Li M DISCO: a database of deeply integrated human single-cell omics data Nucleic Acids Res 2022 50 D596 d602 10.1093/nar/gkab1020 34791375
Li M, et al. DISCO: a database of deeply integrated human single-cell omics data. Nucleic Acids Res. 2022;50:D596-d602.34791375
163. Yuan H CancerSEA: a cancer single-cell state atlas Nucleic Acids Res 2019 47 D900 d908 10.1093/nar/gky939 30329142
Yuan H, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47:D900-d908.30329142
164. Zhao T SC2disease: a manually curated database of single-cell transcriptome for human diseases Nucleic Acids Res 2021 49 D1413 d1419 10.1093/nar/gkaa838 33010177
Zhao T, et al. SC2disease: a manually curated database of single-cell transcriptome for human diseases. Nucleic Acids Res. 2021;49:D1413-d1419.33010177
165. Stingl J Caldas C Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis Nat Rev Cancer 2007 7 791 799 10.1038/nrc2212 17851544
Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7:791–9.17851544
166. Lim E Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers Nat Med 2009 15 907 913 10.1038/nm.2000 19648928
Lim E, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15:907–13.19648928
167. Nguyen QH Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity Nat Commun 2018 9 2028 10.1038/s41467-018-04334-1 29795293
Nguyen QH, et al. Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity. Nat Commun. 2018;9:2028.29795293
168. Bhat-Nakshatri P A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells Cell Rep Med 2021 2 100219 10.1016/j.xcrm.2021.100219 33763657
Bhat-Nakshatri P, et al. A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells. Cell Rep Med. 2021;2:100219.33763657
169. Gray GK A human breast atlas integrating single-cell proteomics and transcriptomics Dev Cell 2022 57 1400 1420.e1407 10.1016/j.devcel.2022.05.003 35617956
Gray GK, et al. A human breast atlas integrating single-cell proteomics and transcriptomics. Dev Cell. 2022;57:1400-1420.e1407.35617956
170. Chung CY Single-cell chromatin analysis of mammary gland development reveals cell-state transcriptional regulators and lineage relationships Cell Rep 2019 29 495 510.e496 10.1016/j.celrep.2019.08.089 31597106
Chung CY, et al. Single-cell chromatin analysis of mammary gland development reveals cell-state transcriptional regulators and lineage relationships. Cell Rep. 2019;29:495-510.e496.31597106
171. Gao ZJ Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype Theranostics 2024 14 3104 3126 10.7150/thno.96163 38855191
Gao ZJ, et al. Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype. Theranostics. 2024;14:3104–26.38855191
172. Loibl S Poortmans P Morrow M Denkert C Curigliano G Breast cancer Lancet 2021 397 1750 1769 10.1016/S0140-6736(20)32381-3 33812473
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–69.33812473
173. Li CM Aging-associated alterations in mammary epithelia and stroma revealed by single-cell RNA sequencing Cell Rep 2020 33 108566 10.1016/j.celrep.2020.108566 33378681
Li CM, et al. Aging-associated alterations in mammary epithelia and stroma revealed by single-cell RNA sequencing. Cell Rep. 2020;33:108566.33378681
174. Pelissier Vatter FA High-dimensional phenotyping identifies age-emergent cells in human mammary epithelia Cell Rep 2018 23 1205 1219 10.1016/j.celrep.2018.03.114 29694896
Pelissier Vatter FA, et al. High-dimensional phenotyping identifies age-emergent cells in human mammary epithelia. Cell Rep. 2018;23:1205–19.29694896
175. Proia TA Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate Cell Stem Cell 2011 8 149 163 10.1016/j.stem.2010.12.007 21295272
Proia TA, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell. 2011;8:149–63.21295272
176. Hu L Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers Cancer Res 2021 81 2600 2611 10.1158/0008-5472.CAN-20-2123 33727227
Hu L, et al. Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers. Cancer Res. 2021;81:2600–11.33727227
177. Nee K Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis Nat Genet 2023 55 595 606 10.1038/s41588-023-01298-x 36914836
Nee K, et al. Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis. Nat Genet. 2023;55:595–606.36914836
178. Reed AD A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast Nat Genet 2024 56 652 662 10.1038/s41588-024-01688-9 38548988
Reed AD, et al. A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast. Nat Genet. 2024;56:652–62.38548988
179. Welch DR Tumor heterogeneity–A 'contemporary concept' founded on historical insights and predictions Cancer Res 2016 76 4 6 10.1158/0008-5472.CAN-15-3024 26729788
Welch DR. Tumor heterogeneity–A “contemporary concept” founded on historical insights and predictions. Cancer Res. 2016;76:4–6.26729788
180. Meacham CE Morrison SJ Tumour heterogeneity and cancer cell plasticity Nature 2013 501 328 337 10.1038/nature12624 24048065
Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328–37.24048065
181. McGranahan N Swanton C Biological and therapeutic impact of intratumor heterogeneity in cancer evolution Cancer Cell 2015 27 15 26 10.1016/j.ccell.2014.12.001 25584892
McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27:15–26.25584892
182. Yeo SK Guan JL Breast cancer: multiple subtypes within a tumor? Trends Cancer 2017 3 753 760 10.1016/j.trecan.2017.09.001 29120751
Yeo SK, Guan JL. Breast cancer: multiple subtypes within a tumor? Trends Cancer. 2017;3:753–60.29120751
183. Lehmann BD Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 2011 121 2750 2767 10.1172/JCI45014 21633166
Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.21633166
184. Jiang YZ Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies Cancer Cell 2019 35 428 440.e425 10.1016/j.ccell.2019.02.001 30853353
Jiang YZ, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428-440.e425.30853353
185. Jin X, et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023;55:1696–1708.
186. Polyak K Breast cancer: origins and evolution J Clin Invest 2007 117 3155 3163 10.1172/JCI33295 17975657
Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117:3155–63.17975657
187. Lawson DA Kessenbrock K Davis RT Pervolarakis N Werb Z Tumour heterogeneity and metastasis at single-cell resolution Nat Cell Biol 2018 20 1349 1360 10.1038/s41556-018-0236-7 30482943
Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z. Tumour heterogeneity and metastasis at single-cell resolution. Nat Cell Biol. 2018;20:1349–60.30482943
188. Karaayvaz M Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq Nat Commun 2018 9 3588 10.1038/s41467-018-06052-0 30181541
Karaayvaz M, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018;9:3588.30181541
189. Xu L, et al. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep Med. 2024;5:101511.
190. Liu SQ Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer J Hematol Oncol 2022 15 19 10.1186/s13045-022-01236-0 35241110
Liu SQ, et al. Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer. J Hematol Oncol. 2022;15:19.35241110
191. de Visser KE Joyce JA The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth Cancer Cell 2023 41 374 403 10.1016/j.ccell.2023.02.016 36917948
de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.36917948
192. Oliveira G Wu CJ Dynamics and specificities of T cells in cancer immunotherapy Nat Rev Cancer 2023 23 295 316 10.1038/s41568-023-00560-y 37046001
Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23:295–316.37046001
193. Downs-Canner SM Meier J Vincent BG Serody JS B cell function in the tumor microenvironment Annu Rev Immunol 2022 40 169 193 10.1146/annurev-immunol-101220-015603 35044794
Downs-Canner SM, Meier J, Vincent BG, Serody JS. B cell function in the tumor microenvironment. Annu Rev Immunol. 2022;40:169–93.35044794
194. Ugel S Canè S De Sanctis F Bronte V Monocytes in the Tumor Microenvironment Annu Rev Pathol 2021 16 93 122 10.1146/annurev-pathmechdis-012418-013058 33497262
Ugel S, Canè S, De Sanctis F, Bronte V. Monocytes in the Tumor Microenvironment. Annu Rev Pathol. 2021;16:93–122.33497262
195. Kloosterman DJ Akkari L Macrophages at the interface of the co-evolving cancer ecosystem Cell 2023 186 1627 1651 10.1016/j.cell.2023.02.020 36924769
Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023;186:1627–51.36924769
196. Chhabra Y Weeraratna AT Fibroblasts in cancer: Unity in heterogeneity Cell 2023 186 1580 1609 10.1016/j.cell.2023.03.016 37059066
Chhabra Y, Weeraratna AT. Fibroblasts in cancer: Unity in heterogeneity. Cell. 2023;186:1580–609.37059066
197. Ren X Insights gained from single-cell analysis of immune cells in the tumor microenvironment Annu Rev Immunol 2021 39 583 609 10.1146/annurev-immunol-110519-071134 33637019
Ren X, et al. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu Rev Immunol. 2021;39:583–609.33637019
198. Lavie D Ben-Shmuel A Erez N Scherz-Shouval R Cancer-associated fibroblasts in the single-cell era Nat Cancer 2022 3 793 807 10.1038/s43018-022-00411-z 35883004
Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3:793–807.35883004
199. Savas P Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis Nat Med 2018 24 986 993 10.1038/s41591-018-0078-7 29942092
Savas P, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24:986–93.29942092
200. Azizi E Single-cell map of diverse immune phenotypes in the breast tumor microenvironment Cell 2018 174 1293 1308.e1236 10.1016/j.cell.2018.05.060 29961579
Azizi E, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174:1293-1308.e1236.29961579
201. Pal B A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast Embo J 2021 40 e107333 10.15252/embj.2020107333 33950524
Pal B, et al. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. Embo J. 2021;40:e107333.33950524
202. Wagner J A single-cell atlas of the tumor and immune ecosystem of human breast cancer Cell 2019 177 1330 1345.e1318 10.1016/j.cell.2019.03.005 30982598
Wagner J, et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. 2019;177:1330-1345.e1318.30982598
203. Morad G Helmink BA Sharma P Wargo JA Hallmarks of response, resistance, and toxicity to immune checkpoint blockade Cell 2021 184 5309 5337 10.1016/j.cell.2021.09.020 34624224
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184:5309–37.34624224
204. Liu Y Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy Clin Cancer Res 2020 26 970 977 10.1158/1078-0432.CCR-19-1040 31615933
Liu Y, et al. Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26:970–7.31615933
205. Wang L PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer Cell Rep Med 2024 5 101420 10.1016/j.xcrm.2024.101420 38382468
Wang L, et al. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. Cell Rep Med. 2024;5:101420.38382468
206. Bartoschek M Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing Nat Commun 2018 9 5150 10.1038/s41467-018-07582-3 30514914
Bartoschek M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9:5150.30514914
207. Costa A Fibroblast heterogeneity and immunosuppressive environment in human breast cancer Cancer Cell 2018 33 463 479.e410 10.1016/j.ccell.2018.01.011 29455927
Costa A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33:463-479.e410.29455927
208. Cords L Cancer-associated fibroblast classification in single-cell and spatial proteomics data Nat Commun 2023 14 4294 10.1038/s41467-023-39762-1 37463917
Cords L, et al. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat Commun. 2023;14:4294.37463917
209. Ye J, et al. Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression. Cancer Discov. 2024;14:1302–23.
210. Kieffer Y Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer Cancer Discov 2020 10 1330 1351 10.1158/2159-8290.CD-19-1384 32434947
Kieffer Y, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10:1330–51.32434947
211. Croizer H Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer Nat Commun 2024 15 2806 10.1038/s41467-024-47068-z 38561380
Croizer H, et al. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nat Commun. 2024;15:2806.38561380
212. Potente M Gerhardt H Carmeliet P Basic and therapeutic aspects of angiogenesis Cell 2011 146 873 887 10.1016/j.cell.2011.08.039 21925313
Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873–87.21925313
213. Augustin HG, Koh GY. Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology. Science. 2017;357:eaal2379.
214. Potente M Mäkinen T Vascular heterogeneity and specialization in development and disease Nat Rev Mol Cell Biol 2017 18 477 494 10.1038/nrm.2017.36 28537573
Potente M, Mäkinen T. Vascular heterogeneity and specialization in development and disease. Nat Rev Mol Cell Biol. 2017;18:477–94.28537573
215. Zeng Q Understanding tumour endothelial cell heterogeneity and function from single-cell omics Nat Rev Cancer 2023 23 544 564 10.1038/s41568-023-00591-5 37349410
Zeng Q, et al. Understanding tumour endothelial cell heterogeneity and function from single-cell omics. Nat Rev Cancer. 2023;23:544–64.37349410
216. Geldhof V Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast Nat Commun 2022 13 5511 10.1038/s41467-022-33052-y 36127427
Geldhof V, et al. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast. Nat Commun. 2022;13:5511.36127427
217. Liang Y Zhang H Song X Yang Q Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets Semin Cancer Biol 2020 60 14 27 10.1016/j.semcancer.2019.08.012 31421262
Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.31421262
218. Paul MR Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets J Clin Invest 2020 130 4252 4265 32657779
Paul MR, et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest. 2020;130:4252–65.32657779
219. Obradović MMS Glucocorticoids promote breast cancer metastasis Nature 2019 567 540 544 10.1038/s41586-019-1019-4 30867597
Obradović MMS, et al. Glucocorticoids promote breast cancer metastasis. Nature. 2019;567:540–4.30867597
220. Xiao Y Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation Cancer Cell 2021 39 423 437.e427 10.1016/j.ccell.2020.12.012 33450198
Xiao Y, et al. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell. 2021;39:423-437.e427.33450198
221. Chang G YTHDF3 Induces the Translation of m(6)A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis Cancer Cell 2020 38 857 871.e857 10.1016/j.ccell.2020.10.004 33125861
Chang G, et al. YTHDF3 Induces the Translation of m(6)A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell. 2020;38:857-871.e857.33125861
222. Lorusso G Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation Sci Transl Med 2022 14 eaax8933 10.1126/scitranslmed.aax8933 36070364
Lorusso G, et al. Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation. Sci Transl Med. 2022;14:eaax8933.36070364
223. Liu Y FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer Sci Adv 2023 9 eadg7112 10.1126/sciadv.adg7112 37595040
Liu Y, et al. FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer. Sci Adv. 2023;9:eadg7112.37595040
224. Gerstberger S Jiang Q Ganesh K Metastasis Cell 2023 186 1564 1579 37059065
Gerstberger S, Jiang Q, Ganesh K. Metastasis Cell. 2023;186:1564–79.37059065
225. Casasent AK Multiclonal invasion in breast tumors identified by topographic single cell sequencing Cell 2018 172 205 217.e212 10.1016/j.cell.2017.12.007 29307488
Casasent AK, et al. Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell. 2018;172:205-217.e212.29307488
226. Peinado H Pre-metastatic niches: organ-specific homes for metastases Nat Rev Cancer 2017 17 302 317 10.1038/nrc.2017.6 28303905
Peinado H, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17:302–17.28303905
227. Zou Y The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer Adv Sci (Weinh) 2023 10 e2203699 10.1002/advs.202203699 36529697
Zou Y, et al. The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci (Weinh). 2023;10:e2203699.36529697
228. Zhou H, Lei PJ, Padera TP. Progression of Metastasis through Lymphatic System. Cells. 2021;10:627.
229. Brown M Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice Science 2018 359 1408 1411 10.1126/science.aal3662 29567714
Brown M, et al. Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science. 2018;359:1408–11.29567714
230. Lei PJ, et al. Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes. J Exp Med. 2023;220:e20221847.
231. Liu T Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients Nat Commun 2022 13 6823 10.1038/s41467-022-34581-2 36357424
Liu T, et al. Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients. Nat Commun. 2022;13:6823.36357424
232. Sun J A vertebral skeletal stem cell lineage driving metastasis Nature 2023 621 602 609 10.1038/s41586-023-06519-1 37704733
Sun J, et al. A vertebral skeletal stem cell lineage driving metastasis. Nature. 2023;621:602–9.37704733
233. Wu Q SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches Cell Res 2023 33 464 478 10.1038/s41422-023-00810-6 37142671
Wu Q, et al. SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches. Cell Res. 2023;33:464–78.37142671
234. Fendt SM Frezza C Erez A Targeting metabolic plasticity and flexibility dynamics for cancer therapy Cancer Discov 2020 10 1797 1807 10.1158/2159-8290.CD-20-0844 33139243
Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 2020;10:1797–807.33139243
235. Bergers G Fendt SM The metabolism of cancer cells during metastasis Nat Rev Cancer 2021 21 162 180 10.1038/s41568-020-00320-2 33462499
Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21:162–80.33462499
236. Davis RT Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing Nat Cell Biol 2020 22 310 320 10.1038/s41556-020-0477-0 32144411
Davis RT, et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat Cell Biol. 2020;22:310–20.32144411
237. Liu YM Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination Adv Sci (Weinh) 2023 10 e2205395 10.1002/advs.202205395 36594618
Liu YM, et al. Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination. Adv Sci (Weinh). 2023;10:e2205395.36594618
238. Wilcock P Webster RM The breast cancer drug market Nat Rev Drug Discov 2021 20 339 340 10.1038/d41573-021-00018-6 33483705
Wilcock P, Webster RM. The breast cancer drug market. Nat Rev Drug Discov. 2021;20:339–40.33483705
239. Cai YW Shao ZM Yu KD De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort Cancer 2022 128 1748 1756 10.1002/cncr.34155 35213037
Cai YW, Shao ZM, Yu KD. De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort. Cancer. 2022;128:1748–56.35213037
240. Zelnak AB O'Regan RM Optimizing endocrine therapy for breast cancer J Natl Compr Canc Netw 2015 13 e56 64 10.6004/jnccn.2015.0125 26285250
Zelnak AB, O’Regan RM. Optimizing endocrine therapy for breast cancer. J Natl Compr Canc Netw. 2015;13:e56-64.26285250
241. Pondé NF Zardavas D Piccart M Progress in adjuvant systemic therapy for breast cancer Nat Rev Clin Oncol 2019 16 27 44 10.1038/s41571-018-0089-9 30206303
Pondé NF, Zardavas D, Piccart M. Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 2019;16:27–44.30206303
242. Hanker AB Sudhan DR Arteaga CL Overcoming endocrine resistance in breast cancer Cancer Cell 2020 37 496 513 10.1016/j.ccell.2020.03.009 32289273
Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496–513.32289273
243. Brady SW Combating subclonal evolution of resistant cancer phenotypes Nat Commun 2017 8 1231 10.1038/s41467-017-01174-3 29093439
Brady SW, et al. Combating subclonal evolution of resistant cancer phenotypes. Nat Commun. 2017;8:1231.29093439
244. Griffiths JI Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy Nat Cancer 2021 2 658 671 10.1038/s43018-021-00215-7 34712959
Griffiths JI, et al. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. Nat Cancer. 2021;2:658–71.34712959
245. Choong GM Cullen GD O'Sullivan CC Evolving standards of care and new challenges in the management of HER2-positive breast cancer CA Cancer J Clin 2020 70 355 374 10.3322/caac.21634 32813307
Choong GM, Cullen GD, O’Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020;70:355–74.32813307
246. Chen YF Xu YY Shao ZM Yu KD Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions Cancer Commun (Lond) 2023 43 297 337 10.1002/cac2.12387 36357174
Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2023;43:297–337.36357174
247. Cai YW Shao ZM Yu KD Determining the optimal (neo)adjuvant regimen for human epidermal growth factor receptor 2-positive breast cancer regarding survival outcome: a network meta-analysis Front Immunol 2022 13 919369 10.3389/fimmu.2022.919369 35844533
Cai YW, Shao ZM, Yu KD. Determining the optimal (neo)adjuvant regimen for human epidermal growth factor receptor 2-positive breast cancer regarding survival outcome: a network meta-analysis. Front Immunol. 2022;13:919369.35844533
248. Xiao Y Predicting pathological complete response in neoadjuvant dual blockade with trastuzumab and pertuzumab in HER2 gene amplified breast cancer Front Immunol 2022 13 877825 10.3389/fimmu.2022.877825 35663978
Xiao Y, et al. Predicting pathological complete response in neoadjuvant dual blockade with trastuzumab and pertuzumab in HER2 gene amplified breast cancer. Front Immunol. 2022;13:877825.35663978
249. Swain SM Shastry M Hamilton E Targeting HER2-positive breast cancer: advances and future directions Nat Rev Drug Discov 2023 22 101 126 10.1038/s41573-022-00579-0 36344672
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101–26.36344672
250. Du R PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity Drug Resist Updat 2023 68 100947 10.1016/j.drup.2023.100947 36812747
Du R, et al. PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity. Drug Resist Updat. 2023;68:100947.36812747
251. Bianchini G De Angelis C Licata L Gianni L Treatment landscape of triple-negative breast cancer - expanded options, evolving needs Nat Rev Clin Oncol 2022 19 91 113 10.1038/s41571-021-00565-2 34754128
Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113.34754128
252. Leon-Ferre RA Goetz MP Advances in systemic therapies for triple negative breast cancer BMJ 2023 381 e071674 10.1136/bmj-2022-071674 37253507
Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.37253507
253. Yu KD Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial JAMA Oncol 2020 6 1390 1396 10.1001/jamaoncol.2020.2965 32789480
Yu KD, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1390–6.32789480
254. Li J Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III Trial J Clin Oncol 2020 38 1774 1784 10.1200/JCO.19.02474 32275467
Li J, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III. Trial J Clin Oncol. 2020;38:1774–84.32275467
255. Fan L Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial Lancet Oncol 2024 25 184 197 10.1016/S1470-2045(23)00579-X 38211606
Fan L, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024;25:184–97.38211606
256. Wang X Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial JAMA 2021 325 50 58 10.1001/jama.2020.23370 33300950
Wang X, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50–8.33300950
257. Bianchini G Balko JM Mayer IA Sanders ME Gianni L Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nat Rev Clin Oncol 2016 13 674 690 10.1038/nrclinonc.2016.66 27184417
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90.27184417
258. Lee MC Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing Proc Natl Acad Sci U S A 2014 111 E4726 4735 10.1073/pnas.1404656111 25339441
Lee MC, et al. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc Natl Acad Sci U S A. 2014;111:E4726-4735.25339441
259. Kim C Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing Cell 2018 173 879 893.e813 10.1016/j.cell.2018.03.041 29681456
Kim C, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173:879-893.e813.29681456
260. Marsolier J H3K27me3 conditions chemotolerance in triple-negative breast cancer Nat Genet 2022 54 459 468 10.1038/s41588-022-01047-6 35410383
Marsolier J, et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nat Genet. 2022;54:459–68.35410383
261. Waldman AD Fritz JM Lenardo MJ A guide to cancer immunotherapy: from T cell basic science to clinical practice Nat Rev Immunol 2020 20 651 668 10.1038/s41577-020-0306-5 32433532
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–68.32433532
262. Zhang Y Zhang Z The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Cell Mol Immunol 2020 17 807 821 10.1038/s41423-020-0488-6 32612154
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–21.32612154
263. Wang DR Wu XL Sun YL Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response Signal Transduct Target Ther 2022 7 331 10.1038/s41392-022-01136-2 36123348
Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7:331.36123348
264. Li Y Recent advances in therapeutic strategies for triple-negative breast cancer J Hematol Oncol 2022 15 121 10.1186/s13045-022-01341-0 36038913
Li Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.36038913
265. Onkar SS The great immune escape: understanding the divergent immune response in breast cancer subtypes Cancer Discov 2023 13 23 40 10.1158/2159-8290.CD-22-0475 36620880
Onkar SS, et al. The great immune escape: understanding the divergent immune response in breast cancer subtypes. Cancer Discov. 2023;13:23–40.36620880
266. Schmid P Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 2020 21 44 59 10.1016/S1470-2045(19)30689-8 31786121
Schmid P, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.31786121
267. Schmid P Pembrolizumab for early triple-negative breast cancer N Engl J Med 2020 382 810 821 10.1056/NEJMoa1910549 32101663
Schmid P, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.32101663
268. Cortes J Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 2020 396 1817 1828 10.1016/S0140-6736(20)32531-9 33278935
Cortes J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.33278935
269. Bassez A A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer Nat Med 2021 27 820 832 10.1038/s41591-021-01323-8 33958794
Bassez A, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27:820–32.33958794
270. Zhang Y Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer Cancer Cell 2021 39 1578 1593.e1578 10.1016/j.ccell.2021.09.010 34653365
Zhang Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578-1593.e1578.34653365
271. Wculek SK Dendritic cells in cancer immunology and immunotherapy Nat Rev Immunol 2020 20 7 24 10.1038/s41577-019-0210-z 31467405
Wculek SK, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24.31467405
272. Wu SY CCL19(+) dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer Med 2023 4 373 393.e378 10.1016/j.medj.2023.04.008 37201522
Wu SY, et al. CCL19(+) dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med. 2023;4:373-393.e378.37201522
273. Schürch CM coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front Cell 2020 182 1341 1359.e1319 10.1016/j.cell.2020.07.005 32763154
Schürch CM, et al. coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell. 2020;182:1341-1359.e1319.32763154
274. Wang XQ Spatial predictors of immunotherapy response in triple-negative breast cancer Nature 2023 621 868 876 10.1038/s41586-023-06498-3 37674077
Wang XQ, et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621:868–76.37674077
275. Shiao SL Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer Cancer Cell 2024 42 70 84.e78 10.1016/j.ccell.2023.12.012 38194915
Shiao SL, et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024;42:70-84.e78.38194915
276. Du S Yan J Xue Y Zhong Y Dong Y Adoptive cell therapy for cancer treatment Exploration 2023 3 20210058 10.1002/EXP.20210058 37933232
Du S, Yan J, Xue Y, Zhong Y, Dong Y. Adoptive cell therapy for cancer treatment. Exploration. 2023;3:20210058.37933232
277. Harari A Graciotti M Bassani-Sternberg M Kandalaft LE Antitumour dendritic cell vaccination in a priming and boosting approach Nat Rev Drug Discov 2020 19 635 652 10.1038/s41573-020-0074-8 32764681
Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020;19:635–52.32764681
278. Gong Y Klein Wolterink RGJ Wang J Bos GMJ Germeraad WTV Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy J Hematol Oncol 2021 14 73 10.1186/s13045-021-01083-5 33933160
Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73.33933160
279. Dagher OK Posey AD Jr Forks in the road for CAR T and CAR NK cell cancer therapies Nat Immunol 2023 24 1994 2007 10.1038/s41590-023-01659-y 38012406
Dagher OK, Posey AD Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24:1994–2007.38012406
280. Specht J. et al. Abstract P2–09–13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR). Cancer Res 2019;79:P2–09–13-P02–09–13.
281. Gottschlich A Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia Nat Biotechnol 2023 41 1618 1632 10.1038/s41587-023-01684-0 36914885
Gottschlich A, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023;41:1618–32.36914885
282. Anderson ND Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia Nat Med 2023 29 1700 1709 10.1038/s41591-023-02415-3 37407840
Anderson ND, et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nat Med. 2023;29:1700–9.37407840
283. Ma L Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity Cell 2023 186 3148 3165.e3120 10.1016/j.cell.2023.06.002 37413990
Ma L, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148-3165.e3120.37413990
284. Li L Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering Sci Adv 2023 9 eadd6997 10.1126/sciadv.add6997 37494448
Li L, et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023;9:eadd6997.37494448
